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ABSTRACT 
Mycobacterium tuberculosis, the causative agent of tuberculosis (TB) has 
infected approximately 1/3 of the world population, with 9.4 million new TB 
cases in 2008. In addition to increased cases of drug-resistant strains it is 
vital that novel antitubercular compounds are discovered in order to treat 
infections and reduce the time of current TB therapy courses. Natural 
resources such as plants are now being considered as the focus for 
discovering new compounds. Plants have long been investigated as a 
source of antibiotics for the treatment of human disease. New Zealand 
(NZ) contains a unique and diverse flora; however, to current knowledge 
no native plants have been examined for antimycobacterial activity. Using 
ethnobotany as a basis for selection, a total of 58 native plant samples 
were collected and tested for direct antimycobacterial activity. Samples 
were extracted with sterile distilled water (SDW), ethanol (EtOH) or 
methanol (MeOH) and screened for inhibition against the surrogate 
species, Mycobacterium smegmatis. Active plant samples were then 
validated for bacteriostatic activity towards M. bovis BCG and M. 
tuberculosis H37Ra as well as other clinically-important species. Nine 
extracts from the species Laurelia novae-zelandiae, Lophomyrtus bullata, 
Metrosideros excelsa, Myoporum laetum, Pittosporum tenuifolium, 
Pseudopanax crassifolius and Pseudowintera colorata were found to be 
active against M. smegmatis. Two active extracts were the bark and 
cambium extracts of Laurelia novae-zelandiae (Pukatea), which were 
reportedly used by indigenous Māori for the treatment of tubercular 
lesions. Upon further investigation these extracts also demonstrated 
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bactericidal activity towards M. smegmatis as well as bacteriostatic activity 
towards the slow-growing species M. bovis BCG and M. tuberculosis. 
Purification techniques were then performed to improve the efficiency of 
activity and initial exploration of delivery systems was also examined. The 
bioactive extracts determined in this research offer a starting point for 
identifying their chemical basis of antimycobacterial activity with the 
objective of potentially discovering new anti-tubercular drugs. 
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1.1 Background 
Tuberculosis (TB) is an infectious disease that primarily affects the lungs 
and is caused by the slow-growing acid-fast bacillus Mycobacterium 
tuberculosis [1]. Tuberculosis and bacilli infection has afflicted humans for 
thousands of years [2, 3]. Egyptian mummies have been discovered with 
signs of TB infection [4] and even 9000 year old human remains had 
indications of a tubercule contagion [5]. Around the 17th Century there was 
a notable rise in the incidence of TB in England, which was thought to be 
due to the expansion of cities and general population growth [2, 6]. The 
increase in close-contact, poor living conditions and inferior quality health-
care was thought to have exacerbated the spread of TB [2, 6, 7].  
It was not until 1882 that physician Robert Koch identified M. tuberculosis 
as the causative agent of tuberculosis, using his postulates to isolate the 
bacillus [8]. 
 
1.1.1 Pathogenesis of Tuberculosis 
  The primary mechanism of TB infection is by aerosol transmission [1, 9] 
and can only be spread by people that have contracted the active, not 
latent form of TB [10]. Approximately 90% of M. tuberculosis infections will 
be latent, when the mycobacteria are considered ‘dormant’ and do not 
cause disease [10]. When the bacterium has become active, the disease 
can be fatal if left untreated. When the microorganisms are inhaled into the 
lungs, the immune system responds by activation of T-lymphocytes [9]. 
This causes an accumulation of macrophages which leads to the 
formation of granulomas, or ‘tubercules’ [4, 9]. This lesion is a 
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characteristic feature of TB and in most cases will not cause disease, 
leading to a latent state of TB [10]. However, up to 5% of infected 
individuals will progress to an active state of TB within a year of infection 
and up to another 5% will acquire active TB at some point in their life [10]. 
The infected tissue undergoes necrosis and leads to irreversible lung 
damage [9]. Typical symptoms indicative of TB include a chronic cough 
with blood-tinged sputum, fever, night sweats, loss of appetite, fatigue, 
weight loss and tubercular ulcers [9]. TB primarily infects lung tissue which 
is classed as pulmonary TB; though the bacilli can affect other tissues 
such as the lymph nodes, the circulatory system, the central nervous 
system, skin and the gastrointestinal tract. This is then classed as 
extrapulmonary TB [9]. Around 10-15% of active cases are 
extrapulmonary TB; however, this form of disease is increased up to 50% 
if the patient is HIV positive [11, 12].  
 
1.1.2 Epidemiology 
   An estimated one third of the world population is infected with TB bacilli 
[13]. In 2008 the World Health Organization (WHO) reported 9.4 million 
cases of TB, including 500,000 cases of multi-drug resistant TB (MDR-TB) 
[14, 15]. In 2008 approximately 1.8 million people died as a result of TB 
infection [14]. TB has killed more adults than any other single infectious 
agent, including AIDS and malaria [16]. TB is responsible for more than a 
quarter of unnecessary deaths in adults [16].  
  One of the main problems in the persistence and severity of TB is drug 
resistance. Co-infection of TB with Human Immunodeficiency Virus (HIV) 
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is also a major issue, especially in less developed countries where TB is 
most prevalent [17]. An immunocompromised system can affect the 
severity of TB onset. Those that are HIV-positive have an increased 
chance of up to 30 times of progressing to an active state of TB [18]. It is 
approximated that 1.4 million people infected with TB are HIV-positive 
[17], with an estimated 500,000 deaths due to TB among HIV patients 
recorded in 2008 [18]. TB is considered to be the main cause of adult 
deaths with HIV [13, 17].  
   In 1993, TB was declared a global emergency by the WHO [19]. The 
tuberculosis incidence has worsened with the rise in drug-resistant strains 
of M. tuberculosis, increased HIV infections, use of different healthcare 
schemes among countries and the lack of care in regards to TB control 
programs [17]. In 2006 WHO, in conjunction with the Stop TB Partnership 
developed a ‘Stop Tuberculosis’ strategy, with the aim to “dramatically 
reduce the global burden of tuberculosis by 2015” and thereby eliminating 
TB as a global health problem by 2050 [1, 17].   
 
1.1.2.1 Epidemiology in New Zealand 
  Tuberculosis is not just an overseas issue. In New Zealand (NZ) there 
were approximately 7 cases per 100,000 of TB [20] and in central 
Auckland there was an incident rate of 12.3 cases per 100,000 in 2007 
[20]. This is higher than the average number of cases in other developed 
countries such as Australia, United States of America (USA) and Canada, 
which have around 4-6 cases per 100,000 [17]. However, this is still lower 
than the incidence rate of 15 cases per 100,000 in the United Kingdom 
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[17]. A possible factor for the high incidence of TB cases in NZ is due to 
high migration rates, with 65% of TB cases due to foreign-born individuals 
[21].  
 
1.1.3 Drug development and treatment  
With the continued existence of TB disease in humans there have been a 
variety of treatments investigated. However, it was not until the 20th 
century that significant events occurred in the development of TB 
treatment. 
In 1912 Bacillus subtilis and Bacillus mesentericus cultures were shown to 
inhibit M. tuberculosis growth [22]. In 1943 streptomycin was isolated from 
Streptomyces griseus. It had such a high efficacy against a broad range of 
organisms that it was quickly manufactured on a large-scale by 1944 [23]. 
There was a sharp decrease in the occurrence of TB after the discovery of 
streptomycin and it was thought that TB could be controlled if not 
eradicated [24].  
In terms of prevention, Albert Calmette and Camille Guérin were the first to 
successfully develop a vaccine against tuberculosis using an attenuated 
bovine-strain labelled ‘BCG’ between 1905 and 1921 [25, 26]. It was then 
put into production, immunizing thousands of children in the United 
Kingdom. It was one of the first major vaccine trials in the United Kingdom 
and a noticeable decrease in the incidence of TB was observed from 1954 
to 1965 [27]. 
  The discovery and production of rifampin (RIF), isoniazid (INH) and 
pyrazinamide (PZA) soon followed, which are current TB drugs used 
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today. RIF binds to the β-subunit of the DNA-dependent RNA polymerase 
enzyme, effectively inhibiting transcription [28]. INH is a powerful pro-drug 
that inhibits fatty acid synthesis once activated by the enzyme catalase-
peroxidase (KatG) [29]. PZA still has a poorly understand mode of action, 
but it is thought that PZA is also a pro-drug that inhibits fatty acid synthesis 
[30]. The efficacy and structure of RIF, INH and PZA as well as other 
major first- and second-line drugs used are shown in Table 1.1.3. 
  Production of these drugs was significant as they enabled the foundation 
of combined drug therapy in order to alleviate the levels of TB as well as 
help avoid the formation of resistant strains [31]. There are now two types 
of drug regimens currently used for the treatment of tuberculosis. There 
are first-line drugs, such as ethambutol (ETH), INH, PZA, RIF and 
streptomycin (STR), as shown in Table 1.1.3. These drugs are first used to 
combat TB. There are also second-line drugs available such as 
capreomycin (CAP), cycloserine (CYS) and kanamycin (KAN) that are 
used when first-line drugs are no longer effective. However, second-line 
drugs tend to be less potent or more toxic than standard first-line drugs 
[32]. 
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TB drug 
 
Line 
 
MIC against 
MTB (H37Rv) 
 
Mode of action 
    
 
Capreomycin (CAP) 
 
Second 
 
2 µg/ml. 
 
Inhibits protein 
synthesis[33] 
 
Cycloserine (CYS) 
 
Second 
 
25 µg/ml. 
 
 
Inhibits cell-wall 
biosynthesis and 
maintenance[34] 
 
Ethambutol (ETH) 
 
First 
 
0.5 µg/ml. 
 
 
Inhibits cell-wall 
biosynthesis[35] 
 
Isoniazid (INH) 
 
First 
 
0.025 µg/ml. 
 
Pro-drug that inhibits 
fatty acid synthesis[29] 
 
Kanamycin (KAN) 
 
 
Second 
 
2 µg/ml. 
 
 
Inhibits protein 
synthesis[36] 
 
Pyrazinamide (PZA) 
 
First 
 
6 - 50 µg/ml 
at pH 5.5 
 
 
Prodrug that leads to 
the inhibition of fatty 
acid synthesis[30] 
 
Rifampin (RIF) 
 
First 
 
0.4 µg/ml 
 
Inhibits protein 
synthesis[28] 
 
Streptomycin (STR) 
 
First 
 
1 µg/ml 
 
 
Inhibits protein 
synthesis[37] 
 
 
Table 1.1.3. List of current TB drugs used.  First- and second-line TB drugs 
currently employed with activity against M. tuberculosis H37Rv and general mode 
of action.  
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Tuberculosis is difficult to treat and requires multiple drugs combined with 
long courses [1]. The course of treatment currently used is a Directly 
Observed Treatment Short-course (DOTS) program, involving different 
combinations of first- and second-line drugs. This course has a period of 
treatment time of usually 6 to 12 months, longer than most antibiotic 
treatments [1]. The epidemiological approach for DOTS therapy involves 5 
major steps, which the WHO states are [38]: 
 
1. Sustained political and financial commitment.  
2.      Diagnosis by quality ensured sputum-smear microscopy.  
3.      Standardized short-course anti-TB treatment (SCC) given under 
direct and supportive observation (DOT).   
 
4.      A regular, uninterrupted supply of high quality anti-TB drugs. 
 
5.       Standardized recording and reporting. 
 
This program is applied with the intention of eradicating tuberculosis and 
to avoid the creation of drug-resistant strains.        
 
1.1.4 Drug resistance 
  Although the discovery of streptomycin was hailed as a miracle antibiotic 
it was not long before resistant-strains appeared [22]. Isolates resistant to 
RIF, INH and PZA also began to surface not long after their production 
[39]. Nevertheless the production of these drugs combined with improved 
health-care standards was thought to be sufficient for controlling the 
spread of TB [40]. Consequently, there was little appeal in continuing 
Chapter One  General Introduction 
  9  
research in discovering new TB drugs. As a result, for 40 years no new TB 
drugs were approved by the Food and Drug Administration (FDA) for 
clinical use [40]. A resurgence of TB in the 1980’s, including drug-resistant 
cases and immunocompromised patients lead to renewed interest in 
developing novel drugs [40].  
  There are now two types of drug-resistant TB that have emerged, 
multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant 
tuberculosis (XDR-TB). MDR-TB is resistant to first line drugs RIF and 
INH, whereas XDR-TB is resistant to second-line drugs such as KAN or 
CAP as well as first-line drugs [15]. These strains of TB can be up to 250 
times more expensive to treat than standard TB as they do not respond to 
the regular treatment courses provided [41]. MDR-TB and XDR-TB can 
take years to be treated with more toxic and less effective drugs [41]. 
  There are multiple reasons for the development of drug-resistant strains. 
In terms of the nature of the bacteria, mycobacteria have highly sensitive 
drug-efflux systems and can produce enzymes that modify anti-tubercular 
drugs, for example aminoglycoside acetyl transferases [42]. A distinctive 
property of mycobacteria which is likely to contribute to its drug resistance 
is its cell wall, rich in lipids (e.g. mycolic acid), glycolipids, and 
polysaccharides [43]. This highly hydrophobic cell wall acts as a protective 
barrier [42]. A particular feature of TB however, is its ability to survive in an 
active or dormant state, which can provoke resistance [44]. It is these well-
developed evasion systems that can provide mycobacteria with the ability 
to develop resistance.  Random mutations within the gene sequence can 
also occur such as single nucleotide polymorphisms, leading to 
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development of resistance [45]. HIV can also play a factor with the 
perseverance of resistant TB, as it has been shown that a patient has a 
much higher chance of developing MDR- or XDR-TB if they are HIV 
positive [17]. Other factors for the emergence of resistant strains can be 
due to circumstances such as poor diagnosis, use of broad-range or poor 
quality drugs and patients not completing their course of drug treatment 
[46]. TB therapy is particularly problematic with patients not finishing their 
course of treatment. This is due to the long treatment time as well as toxic 
TB drugs. As a result, the patient is more likely to have an aversion to 
completing the course of medication [17]. 
  With the presence of drug-resistant strains of bacteria, WHO has advised 
that new drugs are required to treat TB [47, 48]. Natural resources are 
now being considered as the focus for discovering new compounds with 
novel modes of activity [49, 50]. 
  
1.2 Phytotherapy  
Phytotherapy is the study of natural product extracts such as plants that 
have medicinal uses. Plants have been used for the treatment of human 
diseases well before antibiotics were discovered.  
 
1.2.1 History of Phytotherapy 
Indigenous peoples have known for generations the medicinal value of 
plants. The earliest discovery of plants thought to be used medicinally 
were found on the remains of a Neanderthal man (designated as Shanidar 
IV) from 60,000 B.C.E., from the archaeological site Shanidar Cave in Iraq 
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[51, 52]. The Sumerians, one of the earliest known civilizations had written 
records of the study of herbal medicines from over 5000 years ago [51]. 
Around 2700 B.C.E., during the Han Dynasty the Chinese created a herbal 
book labelled the Shennong Bencao Jing, listing over 300 plants and their 
medicinal application [51]. One of the plants listed was Ephedra sinica that 
was used for the treatment of asthma and colds. E. sinica is still used 
today for traditional treatment and is the source of the alkaloid ephedrine, 
one of the active components used in common decongestants today [53]. 
Around 1500 B.C.E., Egyptians were known to use plants like garlic, 
wormwood, aloe, coriander, saffron, linseed and opium for medicinal 
purposes [51, 54]. This information was recorded on the Ebers Papyrus, a 
document containing approximately 700 descriptions of plants and their 
medicinal purpose [51, 54]. In ancient Greece, Hippocrates recorded the 
medicinal practices of the Greeks (around 460 B.C.E.) in the Corpus 
Hippocraticum, detailing the use of herbs, as well as other beneficial 
medicinal practices such as fresh air and rest [55, 56]. Then around 1025 
C.E., a pharmacopoeia titled ‘The Canon of Medicine’ was written by 
Avicenna, cataloguing the uses of 800 different plants, drugs and minerals 
and their preparations [57, 58]. Avicenna was also the first physician to 
develop a quarantine system after identifying TB as a contagious disease 
and its possible mode of spread [57, 59].  
 
1.2.2 Medicinal value of Phytotherapy 
  South Africa is home to about 10% of tracheophyte plant species (plants 
containing a vascular system) on the planet, yet less than 5% of these 
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species have been scientifically assessed for pharmacological activity [60]. 
However, around 70% of all South Africans utilize their endemic plants for 
medicinal purposes [60]. Bamuamba et al. (2008) found that extracts from 
the South African plant Buddleja sligna and Leyssera gnaphaloides had 
significant antibacterial activity, similar to that of the first-line drug RIF [61]. 
Tabuti et al (2010) recently determined that more than 80 plant species 
have been used by traditional medical practitioners in Uganda to treat 
tuberculosis [62]. Another study characterised leaf, bark and root material 
from trees used as traditional anti-tubercular medicines in South Africa 
[63]. 
 The people of Papua New Guinea used bark from the plant Evodia 
elleryana for the treatment of coughs and fevers [64]. An ethyl acetate 
extract of this plant revealed that it had significant inhibitory activity against 
M. tuberculosis [64]. It was hypothesized that the inhibitory activity was 
due to the presence of alkaloid quinoline metabolites in the plant species 
[65], therefore presenting a potential class of compounds for drug 
development against M. tuberculosis [64]. 
  There is much biodiversity in the Amazonian forest, but few plants have 
been tested for antibacterial activity [66].  Carneiro et al (2008) discovered 
12 Amazonian plant extracts to have antibacterial activity against different 
strains of Mycobacterium smegmatis, Escherichia coli, Streptococcus 
sanguis, Streptococcus oralis, Staphylococcus aureus and Candida 
albicans [66, 67]. Methanol and chloroform extractions displayed high 
antimicrobial activity [66, 67].  
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  A number of plants native to Mexico were used in traditional medicine for 
the treatment of various respiratory diseases and were tested for 
antimycobacterial activity [68-71]. Jimenez-Arellanes et al (2003) screened 
Mexican plants that were used to treat respiratory diseases to investigate 
if they had antitubercular activity against drug resistant strains [68]. It was 
found that five plants (Artemisia ludoviciana, Chamaedora tepejilote, 
Juniperus communis, Lantana hispida and Malva parviflora) had 
antimycobacterial activity against M. tuberculosis H37Rv [68]. A. 
ludoviciana was a particularly important resource in traditional Mexican 
medicine; used to treat coughs, asthma, bronchitis and other ailments [68, 
69]. It was found that the plant A. ludoviciana produced sesquiterpene 
lactones, which were thought to give the plant its antibacterial activity [68, 
69]. Extracts of Citrus aurantifolia, C. sinensis and Olea europaea, also 
from Mexico were found to be active against both drug-susceptible and 
drug-resistant strains of virulent M. tuberculosis [71].  
  It is estimated that less than 10% of the Earth’s higher plant species have 
been analysed for any kind of bioactivity [18]. Thus, there is a need for 
more research to be conducted on plants that have been traditionally used 
by indigenous peoples for the identification of new anti-tubercular drugs. 
 
1.2.3 Plant-derived drugs 
  While today much of the focus has been on screening libraries of 
synthetic compounds for new lead drugs, plants have often provided a 
source of anti-bacterial compounds. One of the first drugs created was 
derived from the compound salicin, found in the bark of Salix alba [72, 73]. 
Chapter One  General Introduction 
  14  
Salicin was converted into salicylic acid which created aspirin, an effective 
painkiller and antipyretic [49, 74].  
The compound aegicerin was isolated from Clavija procera and has been 
shown to have activity against Mycobacterium tuberculosis H37Rv and 
MDR-TB strains [75]. Rhodomyrtone, a compound from the Southeast 
Asian plant Rhodomyrtus tomentosa was found to have potent 
antibacterial activity against a number of clinically-important gram-positive 
species including Enterococcus faecalis, Streptococcus pneumoniae and 
methicillin-resistant Staphylococcus aureus (MRSA) [76]. The drugs 
tetramethylpyrazine (TMP) and tetrandrine (TET) were derived from 
Chinese herbal plants and are used for the treatment of cardiovascular 
disease [77].  
  Nowadays it is estimated that more than 50% of the principal prescription 
drugs in the United States of America (USA) are derived from natural plant 
extracts [78]. Some of the more well-known drugs include the anticancer 
drugs Paclitaxel (Taxol®), derived from Taxus brevifolia [79], Vincristine 
(Oncovin) derived from Catharanthus roseus [80] and Camptothecin 
(Hycamtin®) which is derived from Camptotheca acuminata [81]. In terms 
of new plant-derived TB drugs there are some promising lead compounds, 
especially from the class of alkaloids. The alkaloid tryptanthrin, derived 
from Strobilanthes cusia, could lead to a potential TB drug with its 
considerable activity against the drug sensitive strain M. tuberculosis 
H37Rv [82]. The indole alkaloids ibogaine and voacangine, which were 
isolated from Tabernaemontana citrifolia, displayed promising activity 
against M. tuberculosis, both with a minimum inhibitory concentration 
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(MIC) of 50 µg/ml [83]. Finally the alkaloid cepharanone B, was isolated 
from Piper sanctum and has potential activity against M. tuberculosis 
H37Rv with an MIC of 12 µg/ml [84]. It is possible that native NZ plants will 
provide anti-tubercular compounds that could lead to new TB drugs.  
 
1.2.4 Secondary Metabolites in plants 
  Secondary metabolites are compounds usually present in plants that are 
not involved in any primary functions of the plant’s requirements, for 
example, growth, development and reproduction [85]. Secondary 
metabolites tend to be diverse in size, structure and distribution both within 
plants and between species, yet appear to have no evident metabolic 
purpose even though they persist in all flora [85]. Secondary metabolites 
are likely to have a significant function if the plant expends metabolic 
energy to produce them [85]. It is proposed that plants have developed 
complex systems involving secondary metabolites in order to survive the 
ecological complexity surrounding them. This can include the production of 
chemicals that facilitate protection against predators, whether it be a 
deterrent or poison [49]. Hence, although secondary metabolites do not 
support the essential roles of cell development, the energy spent in the 
production of them is favourable for the plants overall growth and spread 
[49, 86].  
  It is proposed that secondary metabolites could be the source of a plant’s 
antibacterial properties [87]. If these compounds are utilized in the plants 
vascular system to ward off predators (e.g. as an irritant or poison) or used 
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to ward off infection from fungi and bacteria then it is likely that these 
secondary metabolites are a source of antibacterial activity [49]. 
  There are a number of different types of secondary metabolites. The 
classes found to contain the majority of antibacterial compounds are 
alkaloids, flavonoids, terpernoids and phenols [88]. Extracts from the 
South African plant Buddleja sligna and Leyssera gnaphaloides were 
thought to have antibacterial activity due to the presence of triterpenoids 
[61]. The flowers of Chrysanthemum morifolium were used in Chinese 
natural medicine in the treatment of inflammation and fever and it was 
found that different types of triterpenoids from these flowers demonstrated 
antitubercular activity [89]. The isoquinoline alkaloid berberine was 
isolated from Hydrastis canadensis and was found to demonstrate 
antitubercular activity [90]. The leaves of Galenia africana also exhibited 
antimycobacterial activity against M. tuberculosis of which the activity was 
isolated to three flavonoids; (2S)-5,7,2'-trihydroxyflavanone, (E)-3,2',4'-
trihydroxychalcone and (E)-2',4'-dihydroxychalcone [91].  
Therefore, as plants produce thousands of secondary metabolites there is 
much potential for investigating flora as a source for antitubercular activity. 
 
1.3 New Zealand flora  
NZ has a somewhat diverse range of flora and therefore it is possible that 
a wide range of novel compounds are present and unique to NZ flora. 
 
1.3.1 Development of our flora 
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The biodiversity of NZ’s flora can be attributed to the remoteness of its 
land. The land that was to become NZ was separated from the ancient 
supercontinent Gondwana around 65 million years ago, allowing the native 
fauna and flora to evolve in isolation [92]. Consequently, NZ has a 
distinctive range of plants, with approximately 80% of trees and shrubs 
and 40% of ferns that are endemic to the country [92]. The genus 
Podocarpus (e.g. Tōtara) and Nothofagus (e.g. Beeches) show similarities 
to biota linked back to the landmass Gondwana [92], suggesting NZ plants 
are similar to that of ancient flora. Thus, NZ has some of the highest rates 
of endemic species, which implies that diverse and conserved selection of 
plants are more likely to contain novel compounds due to greater 
chemodiversity of secondary metabolites [93]. The diversity is also due to 
the mild temperate climate and general lack of animal predators that has 
allowed the fauna and flora to evolve and adapt unimpeded [92]. Despite 
the years of forestry clearance through the expansion of human 
settlements, there is still plenty of natural vegetation. Around 18% of NZ is 
protected conservation land [94] like that of Otari-Wilton bush or Karori 
Wildlife Sanctuary (Zealandia), therefore providing a wide variety of native 
plants for selection. 
 
1.3.2 Rongoa Māori 
  Arrival of the Māori population from Polynesia occurred sometime around 
1300 A.D. [95]. With the appearance and settlement of a human 
population in NZ, the Māori soon became familiar with the native flora, 
finding uses for it such as tools, building, clothing and medicine [96]. They 
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employed ‘Rongoa Māori’, the traditional practice of using native flora for 
medicinal purposes [96]. This would include the use of leaves, roots, bark 
and flowers. Faith was also considered an important role in Rongoa 
medicine. A ‘Tohunga’ was a form of doctor that had the power of ‘tapu’ 
(meaning sacredness) who knew the medicinal uses of plants and was the 
dispenser of treatments [96]. When European explorers made contact, 
they found the Māori to be vigorous and strong inhabitants with little 
sickness present in the community [96]. In fact, it was recorded that the 
European medicine practitioners were known to rely on the Māori 
remedies when their own stock of drugs was limited [97].  
  Many plants were considered important in Rongoa. The NZ flax 
Phormium tenax was utilized in Rongoa Māori for many remedies. The 
leaves were boiled for the treatment of cuts by applying it as a disinfectant 
[98]. Flax roots were used for treating abscesses and the gum used for 
burns and ringworm [96]. Macropiper excelsum (Kawakawa) was also 
considered a principal plant in Māori medicine, as the leaves were used 
for several remedies. They were applied to wounds as well as used in the 
treatment of rheumatism, arthritis, bruises, bladder problems and chest 
difficulties [96, 99, 100]. The leaf of P. colorata (Horopito) was used to 
treat toothache, skin irritations as well as a painkiller [96, 101]. Overall 
though most of the remedies treated common problems such as pain, 
toothache, wounds, skin irritations and stomach aches [98]. 
  Rongoa Māori is relevant to this research as it the main basis of selection 
of native plants for analysis. If activity is identified then it reinforces the 
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implication that plants used in traditional medicine are likely to contain 
antibacterial compound(s) [49].  
 
 
1.3.3 Antibiotic activity of native New Zealand plants 
Some of the native flora of NZ has already been investigated for various 
bioactivities. The shrub Lophomyrtus bullata (Ramarama) has been 
identified as having activity towards Bacillus subtilis [102]. P. colorata is 
known to have significant activity against Candida albicans [103]. Its 
activity has been isolated to the sesquiterpene dialdehyde polygodial 
[103]. Liverworts have been investigated for bioactivity. The tea trees 
Manuka (Leptospermum scoparium) and Kanuka (Kunzea ericoides) have 
been shown to have antibacterial properties in their honey [104]. The 
liverwort Plagiochila stephensoniana was found to have antifungal activity, 
of which its active component was identified as bibenzyl 4-hydroxy-3’-
methoxybibenzyl [105]. However, to current knowledge NZ plants have not 
been assayed for activity against mycobacteria. Thus, there is a potential 
resource for novel antimycobacterial compounds in NZ flora. 
 
1.4 Aims of Research 
The aim of this research was to investigate the potential antimycobacterial 
activity of native plant extracts. This required the following objectives: 
 
• Collect native plant samples with potential bioactivity 
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This will be achieved by compiling a list of native plants with medicinal 
activity and then collecting the samples from local bush reserves in 
order to build the plant extract library. 
 
 
• Identify native plant extracts with antimycobacterial activity 
The plant samples will be extracted with various solvents and initially 
screened against surrogate species M. smegmatis for the detection of 
antimycobacterial activity. 
 
• Validate plant extracts with antimycobacterial and antibacterial activity  
Positive hits will be tested for bacteriostatic activity against species M. 
bovis BCG, M. tuberculosis H37Ra, S. aureus and E. coli. Bactericidal 
activity will also be determined against M. smegmatis. 
 
• Improve efficiency of extraction and deliver the bioactive extracts in a 
practical application 
Positive hits will be purified and investigated for improved activity by 
means of size exclusion fractionation and solvent phase separation. 
Active plant extracts will also be applied to an aqueous cream for the 
purpose of delivery of the bioactive extract and assessed for inhibitory 
activity in a disc diffusion assay. 
Chapter Two  Materials and Methods 
  21  
 
 
 
CHAPTER TWO: 
Materials and Methods 
 
 
 
 
Chapter Two  Materials and Methods 
  22  
2.1 Bacterial strains and plasmids 
The mycobacterial strains used were M. smegmatis mc2155, M. bovis 
BCG (Pasteur) and M. tuberculosis H37Ra. M. smegmatis and M. bovis 
BCG were labelled with a Green Fluorescent Protein (GFP) marker 
through the introduction of the plasmid pSHIGH + hsp60 by 
electroporation and selection on media containing kanamycin (50 µg/ml) 
as described by Miller et al (2009) [106]. Staphylococcus aureus Newman 
strain was GFP-labelled as previously described [107, 108] and selected 
on media containing erythromycin (30 µg/ml) (Sigma). See Appendix 1 
Section ‘Bacterial strains and plasmids’ for more detail [109]. Escherichia 
coli DH5α was labelled with GFP using pOT11 and selected on media 
containing chloramphenicol (25 µg/ml) (Sigma) as previously described 
[110].   
 
2.2 Culture conditions 
  M. smegmatis mc2155 was cultured on a Luria agar (LA) plate with 
kanamycin (50 µg/ml) (Sigma) at 37°C. Colonies sele cted were inoculated 
in Luria Broth (LB) media containing kanamycin (50 µg/ml), Tween 80 
(0.1% v/v) (Sigma) and D-arabinose (250 µg/ml) (Sigma). 
Both M. bovis and M. tuberculosis cultures were grown in Middlebrook 
7H9 broth supplemented with 10% (v/v) OADC (0.06% Oleic acid, 5% 
BSA, 2% Dextrose, 0.85% NaCl) (Becton, Dickinson and Company), 
glycerol (0.5% v/v) (British Drug Houses) and Tween 80 (0.05% v/v).  
GFP-labelled S. aureus Newman was cultured on LA containing 
erythromycin (30 µg/ml). When inoculated into media, S. aureus was 
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grown in LB with the addition of erythromycin (30 µg/ml) and xylose (0.5% 
w/v) (British Drug Houses).  
E. coli DH5α/pOT11 was cultured on LA containing chloramphenicol (25 
µg/ml). Innoculation into LB media involved the addition of 
chloramphenicol (25 µg/ml) and Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) (100 µg/ml). IPTG was added to induce GFP expression.  
 
2.3 Visualisation of bacteria 
Slides of Mycobacteria smegmatis were prepared by removing 5 µl from 
overnight cultures. The bacteria were viewed under a 1000 x (oil 
immersion) Olympus Provis AX 70TRF Fluorescent Microscope (Olympus 
America Inc) with a Fluorescein Isothiocyanate (FITC) filter used to 
visualise the fluorescent cells. 
 
2.4 Sample collection 
Plant samples were primarily collected from the Karori Wildlife Sanctuary 
(Zealandia) and Otari-Wilton Bush Reserve. Other samples were also 
obtained from Wellington; Kaitoke Regional Park, Upper Hutt and the 
central Wellington area with permission. Samples were also collected from 
the Canterbury and Nelson areas with permission. Leaf, flower, seed or 
bark tissues were collected fresh and stored in plastic bags. Leaves were 
chosen from the same apical node from each branch with similar size and 
colouring. Location, date of collection and details of the species were 
noted. 
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2.5 Solvent extraction 
Approximately 5-10 g of each plant sample was macerated using a 
blender (Breville) and then dried in roughly 20 g of the granular desiccate 
calcium sulphate (British Drug Houses). The dried sample was placed in a 
50 ml conical tube and sterile distilled water (SDW), ethanol (EtOH) or 
methanol (MeOH) were added to give a final concentration of 100 mg/ml. 
Samples were then incubated in a water bath at 55°C  for 1 hour before 
being stored at -80°C for 24 hours. The incubation was performed in order 
to imitate the preparations used in traditional Māori medicine. The 
resulting extract was then centrifuged (Alphatech) at 5000 x g for 15 
minutes before being sterilized through a 0.22 µm filter (Millipore). The 
final extract was stored at -80°C.  
 
2.5.1 Evaporation of extracts 
  Plant samples to be evaporated had 500 µl of extract aliquoted into 1.5 
ml eppendorf tubes and were centrifuged (Labconco centrivap 
concentrator) under vacuum at -100 kPa with 30 bar Hg, at 35°C for 2 
hours. The resulting plant material was then resuspended in the desired 
solvent and sterilized through a 0.22 µm filter. 
 
2.6 Purification of extracts 
 
2.6.1 Size exclusion filtration of extracts 
Approximately 2 ml of plant extract in 50% EtOH or MeOH (or 100% SDW 
if aqueous (AQ) extract) was aliquoted into a 30 kDa filter (Millipore) and 
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centrifuged at 5000 x g for 20 minutes. The filtrate was then aliquoted into 
a 3 kDa filter and centrifuged again at 5000 x g for 20 minutes. About 1 ml 
of SDW was added to each of the filters and sonicated for 10 minutes to 
remove any extract present (retentate). The resulting filtrate and retentate 
were then pipetted into fresh eppendorf tubes and evaporated under 
speed-vacuum, weighed and resuspended in SDW to the desired 
concentration. The final extract was then sterilized through a 0.22 µm filter 
and stored at -80°C until required. 
 
2.6.2 Solvent Phase Separation of extracts 
Ethyl Acetate 
Extracts were evaporated and resuspended in SDW to a concentration of 
100 mg/ml. Approximately 2 ml of extract was added to a glass test tube 
and 2 ml of 99% ethyl acetate (EtOAc) was added. The test tubes were 
then sealed with cotton and parafilm and refrigerated at -80°C for 24 
hours. The AQ (extract) layer was removed and aliquoted into fresh 
eppendorf tubes, which were then evaporated and resuspended in SDW 
again to a final concentration of 10 mg/ml. The extracts were then 
sterilized through a 0.22 µm filter prior to analysis. 
Chloroform 
The extracts were evaporated and resuspended in SDW to a 
concentration of 100 mg/ml. Approximately 2 ml of extract was added to a 
glass test tube and 2 ml of 99% chloroform (CHCl3) was added. The test 
tubes were then sealed with cotton and parafilm and refrigerated at -80°C 
for 24 hours. The AQ (extract) layer was removed and aliquoted into fresh 
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eppendorf tubes, which were then evaporated and resuspended in SDW 
again to a final concentration of 25 mg/ml. The CHCl3 layer was also 
removed and placed into a fresh test tube and evaporated at room 
temperature. Approximately 2 ml of 99% DMSO (Sigma) was added and 
sonicated to dissolve the extract. The extracts were then transferred to 
fresh eppendorf tubes, evaporated and resuspended again in DMSO to a 
final concentration of 10 mg/ml. Extracts were then sterilized through a 
0.22 µm filter prior to analysis. 
 
2.6.3 Size exlusion filtration and SPS 
Approximately 2 ml of plant extract in 50% EtOH or MeOH (or 100% SDW 
if AQ extract) was aliquoted into a 30 kDa filter (Millipore) and centrifuged 
at 5000 x g for 20 minutes. The filtrate was then aliquoted into fresh 
eppendorf tubes (500 µl), evaporated under speed-vacuum and 
resuspended in SDW to a concentration of 100 mg/ml. Approximately 1 ml 
of the filtrate was then aliquoted into a fresh glass test tube. Approximately 
1 ml of 99% EtOAc was then added to the filtrate. The test tubes were 
then sealed with cotton and parafilm and frozen at -80°C for 24 hours. The 
AQ (extract) layer was then removed and aliquoted into fresh eppendorf 
tubes, which were then evaporated and resuspended in SDW to a final 
concentration of 10 mg/ml. The final extracts were sterilized through a 
0.22 µm filter prior to analysis. 
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2.7 Assay Conditions 
 
2.7.1 Bacteriostatic assay  
  Solvent-extracted and fractionated plant samples were examined in a 96-
well microtitre plate (96wp) bacteriostatic assay against M. smegmatis, M. 
bovis, M. tuberculosis, E. coli and S. aureus. Figure 2.7.1 illustrates the 
layout of the bacteriostatic assay. SDW (150 µl) was added to the outer 
lanes of the 96wps to reduce evaporation. The remaining wells were filled 
with 50 µl of liquid media. Plant extracts (10 µl) were pipetted into columns 
2 and 3 of the microtitre plates with a starting concentration of 2 mg/ml. A 
two-fold serial dilution was then performed on each extract starting at 
column 3, aliquoting 30 µl from column 3 into column 4 and so on until 
column 11. Bacterial cells (40 µl) were added to rows B-D at a final OD at 
600 nm (OD600) of 0.2. Rows E-G contained media and extract alone, to 
measure any background optical density or fluorescence associated with 
the extract and media. A number of controls were added to ensure assay 
reliability. Bacterial cells were grown in media alone to allow for 
comparison of bacteriostatic activity against normal growth for each extract 
tested. Standard anti-tubercular drugs RIF and STR were used as positive 
controls, with starting concentrations of 0.1 mg/ml. Solvent controls were 
also used, as some inhibition of bacterial growth could be exhibited by 
some solvents. Inhibition of growth due to the ethanol solvent was 
observed at concentrations of greater than 5% (v/v) for all species tested. 
M. smegmatis, E. coli and S. aureus also had inhibition due to the 
methanol solvent at concentrations greater than 5% (v/v), whereas M. 
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bovis and M. tuberculosis only exhibited inhibition of growth at 
concentrations greater than 10% (v/v). Thus, extracts tested in ethanol or 
methanol had a starting solvent concentration of 2% (v/v) corresponding to 
the final concentration of plant extract. All extracts and controls were 
tested in triplicate. Plates were sealed with nitrocelluose film (Excel 
Scientific) and incubated at 37°C with 200 rpm shak ing. After 24 hours 
plates containing E. coli or S. aureus cultures were read for OD and GFP 
fluorescence. For the Mycobacterium species, M. smegmatis cultures 
were read after 96 hours, M. bovis and M. tuberculosis cultures were read 
after 14 days. Only OD was measured for M. tuberculosis as this organism 
did not contain a plasmid with a GFP insert.  
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Figure 2.7.1. Outline of 96wp set-up for bacteriostatic assay. The outer wells 
are filled with SDW indicated by the dark blue wells (). A) The green wells () 
indicate cells + media in triplicate and the blue wells () indicate media alone in 
triplicate. B) The red wells () indicate the 2:1 serial dilution of extract + cells + 
media in triplicate. The remaining pink wells () indicate extract alone in media in 
triplicate to account for any background absorbance of the extract tested. Drug 
controls were tested in the same format. 
 
A 
B
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2.7.2 Resazurin reduction assay 
An aliquot of 30 µl of resazurin dye (0.02% w/v) (Sigma) was added to 
each well at the end-point of the bacteriostatic assay and incubated at 
37°C for 2 hours. The plates were then read using t he Wallac EnVision® 
Manager 1.12 software program with a General top mirror and 
wavelengths of 530 nm excitation and 590 nm emission. 
 
2.7.3 Bactericidal assay 
M. smegmatis was cultured for 8 days in LB containing kanamycin (50 
µg/ml) until stationary growth phase was reached. The culture was then 
diluted to an OD600 of 1.0 with PBS (1x v/v). A 96-wp assay was then set-
up as previously described in the bacteriostatic assay protocol, with the 
exception of LB media being replaced with PBS 1 x (v/v). After 96 hours 
drug exposure, 30 µl of resazurin dye (0.02% w/v) was added and the 
plates read for any bactericidal activity with wavelengths of 530 nm 
excitation and 590 nm emission. 
 
2.7.4 Cytotoxicity assay 
Murine macrophage cell-line J774 cells (ATCC) and human blood cell-line 
HL-60 (ATCC) were cultured in RPMI 1640 medium (Invitrogen) 
supplemented with 10% (v/v) fetal calf serum (FCS) (Invitrogen) and 
PenStrep (Pencillin 50 units/ml and Streptomycin 50 µg/ml) (Invitrogen). 
Cells were incubated at 37°C in a 5% CO 2 atmosphere for 48 hours. 
Extracts to be tested were serially diluted twofold in a 50 µl volume in a 96 
well tissue culture plates (BD biosciences). Cells were then seeded (50 µl) 
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in the 96 wps to produce a final cell concentration of 104 cells/well. This 
was counted with a hemocytometer for both cell-lines. For J774 cells an 
additional step of trypan blue stain (0.4% v/v) (Sigma) was added before 
counting. A cytotoxic compound, Epothilone A (EpoA) (Merck), was 
included as a positive control with a starting concentration of 25 µg/ml. A 
TB drug control RIF was also included with a starting concentration of 0.4 
mg/ml. All extracts and controls were tested in triplicate. The plates were 
incubated for 48 hours followed by the addition of 10 µl of Alamar Blue dye 
(10% w/v) (Invitrogen). Absorbance readings were then taken after 4 
hours at 570 nm using a VersaMax™ microplate reader (Molecular 
Devices, Inc) and SOFTmax Pro version 3.0 software (Informer 
Technologies, Inc.). 50% inhibitory concentration (IC50) values were 
calculated using SigmaPlot® (version 10.0) (Systat Software, Inc).  
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Figure 2.7.4. Outline of 96wp set-up for cytotoxity assay. The outer wells are 
blank as indicated by the white wells (). The green wells () indicate cells + 
media in triplicate and the blue wells () indicate media alone in triplicate. The 
red wells () indicate the 2:1 serial dilution of extract + cells + media in triplicate. 
In this layout rows B-D indicate one extract tested in triplicate and rows E-G 
indicate a second extract tested in triplicate. Drug controls were tested in the 
same format. 
 
2.8 Data collection and analysis 
An EnVision® 2102 multilabel plate reader (Perkin Elmer, Inc) and the 
Wallace EnVision® Manager 1.12 software program (Perkin Elmer, Inc) 
were used to measure the fluorescent and absorbent GFP and OD signals 
of the microtitre plate cultures. GFP fluorescence was detected using a 
FITC bottom mirror, with excitation and emission wavelengths of 485 nm 
and 510 nm, respectively. OD was measured with an excitation light of 
590 nm. 12-point scans were performed on each well to minimise intra-
well variation, such as ‘clumping’ that can occur with mycobacteria. The 
intrinsic absorbance and fluorescence readings of extracts in media alone 
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were also measured to account for any background signals that were later 
subtracted from the readings for the samples tested. Data was normalised 
by expressing the absorbance and fluorescence values as a percentage of 
a no-drug negative control. Sigmaplot® 10.0 software (version 10.0) was 
used to calculate non-linear dose-response inhibitory curves. A simple 
scatter plot was created with the means of the triplicate data and error 
bars representing standard deviation. A log (common) scale was applied. 
A four parameter logistic curve was calculated to fit the plotted data and as 
a result MIC values and IC50 values with standard errors were generated.  
 
2.9 Disc Diffusion 
For M. smegmatis, 100 µl of culture at an OD600 of 0.2 was spread on LA 
agar containing kanamycin (50 µg/ml) and allowed to dry. For S. aureus 
100 µl of culture at an OD600 of 0.2 was spread on LA agar containing 
erythromycin (30 µg/ml) and allowed to dry. The extract to be tested was 
mixed with an aqueous cream solution (MedCo), to give a final extract 
concentration of 0.5% (w/v). Sterile paper discs (Becton, Dickinson and 
Company) 6 mm in diameter were then dipped in the solution and gently 
placed onto the agar surface. A negative control of just aqueous cream 
alone and positive controls extract alone (i.e. no aqueous cream added) 
and RIF (1 mg/ml) were also tested. The plates were then sealed with 
parafilm and incubated at 37°C for 24 hours for S. aureus and 96 hours for 
M. smegmatis. Any zones of inhibition surrounding the discs were then 
circled and measured. 
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3.1 Introduction 
This research involved collecting native NZ plants and screening them for 
antimycobacterial activity. Hence, a suitable protocol was developed for 
the selection and processing of native plants in preparation for screening 
against M. smegmatis.  
The selection of plant samples was based on native species and 
ethnomedicine [49]. Ethnobotany is the study of how a particular culture 
use and understand plants in terms of food, medicine and religion [111]. 
Ethnomedicine is the study of an indigenous culture and its use of native 
plants for medicinal practices [111]. This is a method of targeted 
collection, selecting plants based on their use in Rongoa Māori (traditional 
medicine). It would be difficult with the timeframe and financial 
circumstances to randomly test native NZ plants for antimycobacterial 
activity. Therefore ethnomedicine was chosen as the focus for selection of 
plants in this study.  
  Many bioactive compounds derived from plants are generally flavonoids, 
alkaloids, terpenoids or phenols [88]. Because of this, the polar solvents 
ethanol and methanol would be used for solvent extraction. An aqueous 
solvent was also chosen as many plants were heated in water for various 
treatments [97].  
Plant extracts were initially screened against the surrogate species, M. 
smegmatis. M. smegmatis is an acid-fast, aerobic, saprophytic bacterium 
[112]. It has a genome 1.7 times larger than M. tuberculosis and is non-
pathogenic, but M. smegmatis does share homology with some virulence 
genes of M. tuberculosis [113]. M. smegmatis also has a fast doubling 
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time of 3-4 hours, therefore it can be a rapid and safe model for testing 
anti-TB compounds in physical containment level-2 laboratories [113].  
  M. smegmatis mc2155 strain was used with a pSHIGH plasmid 
containing a GFP (green fluorescent protein) gene. This protein was 
isolated from Aequorea victoria [114], causing the bacteria to emit a green 
fluorescence which allows for easy detection of bacterial growth under 
inspection [114].  
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3.2 Results 
3.2.1 Medicinal information on native New Zealand plants collected 
for antimycobacterial screening 
A library was complied of native plants selected for sampling. Table 3.2.1 
is a list of the NZ plants collected and any medicinal uses noted. 
 
Plant name (common) 
 
Part 
 
Medicinal Use 
 
                                                                     
Adiantum raddianum (Delta 
maidenhair fern) Leaf Genus Adiantum used medicinally
[115]
                                                     
Agathis australis (Kauri) Leaf Presence of antiviral agathisflavone[116] 
Arthropodium cirratum (New 
Zealand rock lily) 
Leaf Used in Rongoa Māori to treat ulcers[117]  
Asplenium bulbiferum (Hen 
and chicken fern) 
Leaf Genus Asplenium known to have 
antibacterial activity[118] 
Asplenium flaccidum 
(Drooping Spleenwort) 
Leaf Genus Asplenium known to have 
antibacterial activity[118] 
Beilschmiedia tawa (Tawa) Leaf Used in Rongoa Māori to treat sore throat, 
colds, cough[98] 
 Blechnum fluviatile (Kiwikiwi) Leaf Used in Rongoa Māori to treat sore tongue 
and mouth[98] 
Brachyglottis repanda 
(Rangiora) 
Leaf Used in Rongoa Māori to treat wounds, 
ulcers and boils[98]  
Carpodetus serratus (Marble 
leaf) 
Leaf 
seed 
ni 
Clianthus puniceus 
(Kakabeak) 
 
Leaf 
Seed 
Family Fabaceae has recorded 
antibacterial activity[119, 120] 
Cordyline australis (Cabbage 
tree) 
Leaf 
 
Used in Rongoa Māori to treat dysentery, 
diarrhoea and sores[121] 
Cortaderia toetoe (Toetoe) Shoot Used in Rongoa Māori to treat diarrhoea, 
relief of kidney, bladder complaints[97, 122] 
Cyathea dealbata (Ponga) Fronds Used in Rongoa Māori to treat boils[99] 
Dacrydium cupressinum 
(Rimu) 
 
Leaf 
 
Used in Rongoa Māori to treat sores[121] 
Dracophyllum longifolium 
(Inanga) 
Leaf Genus Dracophyllum known to have 
antibacterial activity[123] 
Dodonaea viscosa (Ake ake) 
 
Leaf 
Seed 
Used in Rongoa Māori to treat toothache, 
sore throats and skin irritations[124, 125] 
Dysoxylum spectabile 
(Kohekohe) 
 
Leaf 
 
Used in Rongoa Māori to relieve coughing, 
colds and fevers[96] 
 Exocarpus bidwillii Leaf 
Seed 
Root parasite of other species[126] 
Hebe stricta (Koromiko) Leaf 
Flower 
Leaf was used in Rongoa Māori to treat 
skin problems and ulcers[96, 121] 
Hymenophyton flabellatum 
(Liverwort) 
Leaf Liverworts commonly used medicinally[127] 
Knightia excelsa (Rewarewa) 
 
Leaf Used in Rongoa Māori to relieve 
coughing[121] 
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Kunzea ericoides (Kanuka) Leaf Used in Rongoa Māori to relieve pain, 
headaches and coughs 
Laurelia novae-zelandiae 
(Pukatea) 
Cambium 
 
Bark 
 
Leaf 
Used in Rongoa Māori to treat sores, 
ulcers and tuberculosis[97, 99, 121]  
Used to treat skin conditions, venereal 
disease and used as a painkiller[117] 
Treated toothache[121] 
Leptospermum scoparium 
(Manuka) 
 
Leaf 
Flower 
Leaf was used in Rongoa Māori to treat 
colds, pains, urinary troubles[121] 
Lophomyrtus bullata 
(Ramarama) 
 
Leaf Used in Rongoa Māori to treat bruises[121] 
Macropiper excelsum 
(Kawakawa) 
Leaf Used in Rongoa Māori to treat arthritis, 
rheumatism and chest difficulties[99, 128] 
Melicytus ramiflorus (Mahoe) 
 
Leaf Used in Rongoa Māori to treat rheumatism 
and stomach wounds[121] 
Meryta sinclairii (Puka) Leaf The family Araliaceae has plants used 
medicinally[129] 
Metrosideros excelsa 
(Pohutukawa) 
 
Leaf 
Flower 
 
Flower was used in Rongoa Māori to treat 
sore throats[121] 
Metrosideros umbellata 
(Southern Rata) 
 
Leaf 
 
Genus Metrosideros was used in 
traditional medicine[121] 
Microsorum pustulatum 
(Hound's tongue) 
Leaf Genus Microsorum was used in traditional 
medicine[130] 
Myoporum laetum (Ngaio) Leaf 
 
Used in Rongoa Māori to treat bruises and 
infected wounds[121] 
Nothofagus fusca (Red beech) 
 
Leaf Presence of polyphenolic antioxidant 
nothofagin[131] 
Paesia scaberula (Lace fern) 
 
Leaf Family Dennstaedtiaceae has recorded 
antibacterial activity[132] 
Phormium tenax (New Zealand 
flax) 
Leaf Used in Rongoa Māori to treat cuts and 
constipation[98] 
Pittosporum tenuifolium 
(Kohuhu) 
 
Leaf Used in Rongoa Māori to treat eczema, 
other skin diseases and fever[121] 
Plagiochila stephensoniana 
(Liverwort) 
Leaf Genus Plagiochila known to have 
antibacterial activity[127] 
Pseudopanax arboreus (Five 
finger)  
 
Leaf The family Araliaceae contains plants 
used medicinally[129] 
Pseudopanax crassifolius 
(Lancewood) 
Leaf The family Araliaceae contains plants 
used medicinally[129] 
Pseudowintera colorata 
(Horopito) 
 
Leaf Used in Rongoa Māori to treat toothache, 
skin irritations, and used as a painkiller[96]  
Pteridium esculentum 
(Bracken) 
 
Leaf 
 
Used as an antiseptic as well as treats 
sores[125] 
Rubus cissoides (Bush lawyer) 
 
Leaf Used in Rongoa Māori to treat chest 
congestion, coughs and sore throat[121] 
Schefflera digitata (Seven 
finger) 
Leaf Contains anti-dermatophyte compound 
Falcarindiol[133] 
Sophora microphylla (Kowhai) Leaf Used in Rongoa Māori to treat wounds, 
back, abdominal and internal pains[99] 
Urtica ferox (Stinging nettle) Leaf Genus Urtica has known anti-fungal and 
anti-viral activity[134] 
Vitex lucens (Puriri) 
 
 
Leaf 
Fruit 
Seed 
Used in Rongoa Māori to treat backache, 
ulcers, and sore throats[121] 
Weinmannia racemosa 
(Kamahi) 
Leaf Parts of plant used medicinally to treat 
stomach aches and cuts[121] 
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Table 3.2.1. Medicinal information on native New Zealand plants selected 
for antimycobacterial screening. Information on the native NZ plants was either 
related to Māori medicinal use or any other known anti-infective properties. ni = 
no information available. 
 
 
3.2.2 Location of collection sites 
The majority of samples were collected in the Wellington region, in 
Wellington central, Karori, Otari-Wilton, Ngaio and Kaitoke as shown 
below in Figure 3.2.2. From the Wellington region most of the plants 
collect were form Otari-Wilton bush, a reserve with a wide range of native 
plants with easy access to them for collection. Other reserves included 
Karori Wildlife Sanctuary (Zealandia) and Kaitoke Regional Park. Leaves 
were chosen from the same apical node from each branch with similar size 
and colouring to reduce the amount of variability of compounds present in 
each individual sample.  
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Figure 3.2.2. Plant sample collection sites in New Zealand. Collection sites 
are indicated by the red dots. Inset is an enlarged view of the Wellington region. 
Map reproduced and adapted from Google Maps, ©2010 Google – and © 2010 
MapData Sciences Pty Ltd, PSMA. 
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3.2.3 Conditional information of the samples collected 
The location, season and local conditions were recorded for each sample 
and documented in Table 3.2.3. This information may provide some 
insight into the plants with activity, such as if there is a correlation between 
location, season or condition and the levels of inhibitory activity.  
 
Plant  
 
Area 
 
Season 
 
Conditions 
    
Adiantum raddianum  Ngaio Spring Filtered light, moist, low 
Agathis australis  Otari-Wilton Summer Sunny, dry, slightly damp 
Arthropodium cirrhatum  Ngaio Spring Filtered light, moist 
Asplenium bulbiferum  Upper Hutt Autumn Filtered light, damp, low 
Asplenium flaccidum  Upper Hutt Summer ni 
Beilschmiedia tawa  Upper Hutt Autumn ni 
Blechnum fluviatile  Otari-Wilton Summer Shaded, damp 
Brachyglottis repanda  Karori Summer Filtered light, moist, low 
Carpodetus serratus  S. Island Spring Shaded, damp 
Clianthus puniceus  Tawa Winter Sunny, highland 
Cordyline australis Ngaio Winter Shaded, damp 
Cortaderia toetoe  Karori Summer Sunny, dry 
Cyathea dealbata Otari-Wilton Spring Shaded, damp 
Dacrydium cupressinum  Upper Hutt Autumn ni 
Dracophyllum longifolium  Kaikoura Winter Sunny, dry, highland 
Dodonaea viscosa  Otari-Wilton Autumn Sunny, damp 
Dysoxylum spectabile  Karori Summer Filtered light, damp 
Exocarpus bidwillii Canterbury Winter Sunny, dry 
Hebe speciosa  Otari-Wilton Summer Sunny, dry 
Hymenophyton flabellatum  Otari-Wilton Summer Shaded, damp, lowland 
Knightia excelsa  Otari-Wilton Summer Filtered light, moist 
Kunzea ericoides  Upper Hutt Autumn ni 
Laurelia novae-zelandiae  Otari-Wilton Summer Shaded, wet, lowland 
Leptospermum scoparium  Kelburn  Winter Sunny, dry, highland 
Lophomyrtus bullata  Otari-Wilton Summer Filtered light, moist 
Macropiper excelsum  Otari-Wilton Autumn Filtered light, damp 
Melicytus ramiflorus  Karori Summer Filtered light, moist 
Meryta sinclairii  Kelburn Summer Shaded, damp 
Metrosideros excelsa  Ngaio Summer Sunny, damp 
Metrosideros umbellata  Kaiteriteri Spring ni 
Microsorum pustulatum Karori Summer ni 
Myoporum laetum  Ngaio Winter Sunny, damp 
Nothofagus fusca  Otari-Wilton Summer Sunny, moist 
Paesia scaberula  Otari-Wilton Summer Filtered light 
Pittosporum tenuifolium  Ngaio Winter Sunny, dry 
Plagiochila stephensoniana  Otari-Wilton Summer Shaded, damp 
Pseudopanax arboreus   Ngaio Winter Shaded, damp 
Pseudopanax crassifolius  Otari-Wilton Spring Filtered light, moist 
Pseudowintera colorata  Nelson Spring ni 
Pteridium esculentum  Karori Summer Filtered light, moist 
Rubus cissoides  Moutere Hill Spring ni 
Schefflera digitata  Ngaio Winter Shaded, damp 
Sophora microphylla  Ngaio Winter Shaded, damp 
Urtica ferox  Otari-Wilton Summer Shaded, moist 
Vitex lucens  Kaitoke Spring Filtered light, damp 
Weinmannia racemosa  Upper Hutt Autumn ni 
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Table 3.2.3. Information of the samples collected. The location, season and 
local conditions were recorded for each sample. ni = no information recorded. 
 
3.2.4 Development of Solvent Extraction 
The leaf of M. excelsa was tested in various conditions to validate the 
protocol that was in development. It was questioned that, under solvent 
extraction, if dried plant material would have improved antimycobacterial 
activity compared to fresh. It also was hypothesized that heating the 
sample during the extraction process would have better activity than if 
tested fresh. In traditional medicine a lot of plants were boiled before 
treatment [97]. Thus, it was queried if a period of incubation would help 
increase the yield of bioactive compounds extracted and thus increase the 
potential activity of the sample. In the first condition the leaf extract was 
tested fresh as well as dried with a desiccate. There was no incubation 
involved at this stage. As shown in Table 3.2.4 it appears that there was a 
higher yield and lower MIC with the dried extract than when tested fresh. 
In the second condition a dried sample of leaf was added to MeOH and 
either incubated at 55°C or had no incubation invol ved. The solvent of the 
resulting extracts was then evaporated and the yield of the remaining 
extract was determined. The extracts were then resuspended in MeOH 
and analysed for antimycobacterial activity against M. smegmatis to give 
an MIC. The two conditions gave similar yields, but the extract that was 
incubated had an MIC of 0.75 mg/ml, whereas the MIC was more than 2 
mg/ml for the extract with no incubation performed. 
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Table 3.2.4. Yield and MIC of M. excelsa methanol leaf extract in various 
extraction conditions. The leaf MeOH extract of M. excelsa was tested in 
various conditions to validate the protocol that was in development. In the first 
condition, the leaf extract was tested ‘fresh’ as well as ‘dried’ with a desiccate. In 
the second condition a dried sample of leaf was either incubated at 55°C or had 
no incubation performed. The resulting yield was weighed and then resuspended 
in MeOH before screening against M. smegmatis to determine the MIC.  
 
 
 
3.2.5 Initial Screening of Native Plants against M. smegmatis 
The library of extracts was screened against M. smegmatis for initial 
antimycobacterial activity. The EtOH and MeOH solvents were tested at a 
starting solvent concentration of 2% which did not affect normal growth of 
the bacteria. A minimum of 90% inhibition was considered to be an active 
extract. As shown below in Table 3.2.5 the nine extracts from seven 
species (L. novae-zelandiae, L. bullata, M. excelsa, M. laetum, P. 
tenuifolium, P. crassifolius, P. colorata) were found to cause ≥ 90% 
inhibition.  
 
 
Condition 
 
Yield (g) 
 
MIC (mg/ml) 
 
 
 
 
Fresh 0.0118 >2 
Dried 0.0184 0.9 
   
No Incubation 0.01 >2 
Incubation 
 
0.0168 
 
0.75 
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Plant  
 
 
Part 
 
 
AQ 
 
EtOH 
 
MeOH 
 
 %  inhibition 
 
Adiantum raddianum  
 
Leaf 
 
14 
 
53 
 
63 
Agathis australis  Leaf 35 18 21 
Arthropodium cirrhatum  Leaf 40 16 24 
Asplenium bulbiferum  Leaf 4 12 6 
Asplenium flaccidum  Leaf 25 5 0 
Beilschmiedia tawa  Leaf 19 6 11 
Blechnum fluviatile  Leaf 35 60 2 
Brachyglottis repanda  Leaf 41 27 32 
Carpodetus serratus  Leaf 
Seed 
3 
0 
11 
21 
44 
38 
Clianthus puniceus  Leaf 
Seed 
0 
19 
8 
56 
34 
25 
Cordyline australis Leaf 24 100 79 
Cortaderia toetoe  Leaf 15 93 20 
Cyathea dealbata Leaf 49 36 41 
Dacrydium cupressinum  Leaf 58 72 79 
Dracophyllum longifolium  Leaf 23 83 56 
Dodonaea viscosa  Leaf 
Seed 
54 
7 
6 
22 
46 
26 
Dysoxylum spectabile  Leaf 68 57 68 
Exocarpus bidwillii Leaf 
Seed 
31 
1 
30 
43 
4 
33 
Hebe speciosa  Leaf 
Flower 
50 
89 
12 
0 
94 
10 
Hymenophyton flabellatum  Leaf 48 44 7 
Knightia excelsa  Leaf 73 80 37 
Kunzea ericoides  Leaf 79 39 3 
Laurelia novae-zelandiae  Leaf 
Cambium 
Bark 
Stem 
87 
70 
100 
67 
19 
33 
90 
42 
68 
100 
69 
0 
Leptospermum scoparium  Leaf 
Flower 
56 
55 
69 
62 
84 
50 
Lophomyrtus bullata  Leaf 98 97 20 
Macropiper excelsum  Leaf 41 43 7 
Melicytus ramiflorus  Leaf 57 87 21 
Meryta sinclairii  Leaf 86 7 4 
Metrosideros excelsa  Leaf 
Flower 
90 
91 
69 
100 
100 
70 
Metrosideros umbellata  Leaf 23 86 80 
Microsorum pustulatum Leaf 0 0 28 
Myoporum laetum  Leaf 100 37 16 
Nothofagus fusca  Leaf 22 0 11 
Paesia scaberula  Leaf 50 36 33 
Pittosporum tenuifolium  Leaf 82 100 23 
Plagiochila stephensoniana  Leaf 0 37 32 
Pseudopanax arboreus   Leaf 76 40 37 
Pseudopanax crassifolius  Leaf 7 100 82 
Pseudowintera colorata  Leaf 88 94 100 
Pteridium esculentum  Leaf 65 3 13 
Rubus cissoides  Leaf 50 90 75 
Schefflera digitata  Leaf 64 87 75 
Sophora microphylla  Leaf 33 1 64 
Urtica ferox  Leaf 43 51 46 
Vitex lucens  Leaf 
Fruit 
Seed 
15 
27 
48 
32 
69 
34 
28 
7 
5 
Weinmannia racemosa  Leaf 14 34 51 
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Table 3.2.5. Inhibition levels of native New Zealand plants with respect to M. 
smegmatis. Plants were extracted in an AQ, EtOH or MeOH solvent and 
screened against M. smegmatis. Levels of inhibition were calculated by 
expressing the GFP fluorescence values as a percentage compared to a no-drug 
negative control. 100% represents complete inhibition of M. smegmatis growth. 
All extracts were tested at a starting concentration of 2 mg/ml.  
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3.2.6 Summary of Native Plant Extracts active against M. smegmatis 
Of the 46 native NZ plants initially tested, 7 plant species displayed 
antimycobacterial activity against M. smegmatis. Laurelia novae-
zelandiae, Lophomyrtus bullata, Metrosideros excelsa, Myoporum laetum, 
Pittosporum tenuifolium, Pseudopanax crassifolius and Pseudowintera 
colorata had extracts that showed inhibition towards M. smegmatis, with 
activity specific to one solvent; water, EtOH or MeOH. 
 
 
Table 3.2.6. Antimycobacterial activity of plant extracts against M. 
smegmatis. ‘+’ indicates ≥ 90% inhibition of M. smegmatis growth at a 
concentration of 2 mg/ml or lower. 
 
 
 
 
 
Plant species 
 
Common 
Name 
 
 
Part 
 
Location 
 
 
AQ  
 
EtOH  
 
MeOH  
 
Laurelia novae-
zelandiae  
 
Pukatea 
 
Bark 
 
 
Otari-
Wilton 
 
+ 
 
— 
 
— 
  
Cambium Otari-
Wilton 
— — + 
Lophomyrtus 
bullata  
Ramarama Leaf Otari-
Wilton 
— — + 
Metrosideros 
excelsa   
Pohutukawa Leaf 
 
Ngaio  — — + 
  
Flower Ngaio — + — 
Myoporum 
laetum 
Ngaio Leaf Ngaio + — — 
Pittosporum 
tenuifolium  
Kohuhu Leaf Ngaio — + — 
Pseudopanax 
crassifolius  
Lancewood Leaf Otari-
Wilton 
— + — 
Pseudowintera 
colorata  
 
Horopito Leaf Nelson — — + 
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3.2.7 Comparison of GFP and OD results of active extracts against M. 
smegmatis 
The most active extract was derived from L. novae-zelandiae (Pukatea). 
The bark of L. novae-zelandiae generated an IC50 value of 0.02 mg/ml and 
the cambium had an IC50 of 0.25 mg/ml (Table 3.2.7). Significant activity 
was also observed with respect to the leaf, IC50 of 0.11 mg/ml, and flower, 
IC50 of 0.41 mg/ml, of M. excelsa. P. tenuifolium and P. colorata leaves 
were less active with IC50 values of 0.78 mg/ml and 0.74 mg/ml, 
respectively (Table 3.2.7). The MIC and IC50 values determined by OD 
were higher than those determined by GFP. 
 
 
Table 3.2.7. MIC and IC50 values for GFP and OD of active crude plant 
extracts with respect to M. smegmatis. Extract and drug control values are in 
mg/ml. ‘±’ denotes standard error between triplicate results. 
 
 
 
 
Plant 
 
 
Part  
 
 
GFP 
 
 
 
OD 
 
  MIC IC50  MIC IC50 
 
L. novae-zelandiae 
 
Bark 
  
0.04 
 
0.02 ± 0.004 
  
0.32 
 
0.29 ± 0.13 
 
Cambium 
 
0.50 0.25 ± 0.01 
 
0.50 0.25 ± 0.02 
L. bullata Leaf 
 
1.00 0.31 ± 0.15 
 
2.00 0.024 ± 0.04 
M. excelsa Leaf 
 
0.63 0.11 ± 0.06 
 
1.25 0.078 ± 0.02 
 
Flower 
 
0.63 0.41 ± 0.06 
 
2.0 1.36 ± 1.53 
M. laetum Leaf 
 
0.63 0.34 ± 0.02 
 
2.0 0.46 ± 0.11 
P. tenuifolium Leaf 
 
2.00 0.78 ± 0.34 
 
2.0 1.49 ± 0.41 
P. crassifolius Leaf 
 
0.63 0.31 ± 0.01 
 
1.25 0.74 ± 0.72 
P. colorata Leaf 
 
1.25 0.74 ± 0.40 
 
2.0 1.25 ± 0.17 
RIF - 
 
0.013 0.003 ± 
0.001 
 
 
0.013 0.004 ± 
0.001 
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3.2.7.1 Bacteriostatic inhibition curves of extracts with activity 
against M. smegmatis 
Dose-response experiments were performed on the active extracts that 
were found to have ≥ 90% inhibition in the initial screen against M. 
smegmatis. Figure 3.2.7.1 depicts the bacteriostatic curves for the two 
most active extracts, the bark and cambium of L. novae-zelandiae. See 
Appendix 2 for the bacteriostatic curves of the remaining active extracts.  
 
 
 
 
 
 
 
 
Figure 3.2.7.1. Bacteriostatic inhibition curves for bark and cambium 
extracts of L. novae-zelandiae against M. smegmatis. A) AQ bark extract. B) 
MeOH cambium extract. Values are based on GFP results. 100% represents 
complete growth of M. smegmatis cells compared to the untreated control. Error 
bars denote standard deviation between triplicate values. 
 
 
 
 
 
 
 
Concentration (mg/ml)
0.0001 0.001 0.01 0.1 1 10
M
.
 
sm
e
gm
a
tis
 
gr
o
w
th
 
(%
)
0
20
40
60
80
100
120
140
Concentration (mg/ml)
0.0001 0.001 0.01 0.1 1 10
M
.
 
sm
e
gm
a
tis
 
gr
o
w
th
 
(%
)
0
20
40
60
80
100
120
140
IC50 = 0.02 ± 0.004  
 
IC50 = 0.25 ± 0.01  A B
Chapter Three                               Development of the Plant Extract Library 
  49  
3.3 Discussion 
3.3.1 Construction of Plant Extract Library 
Ethnobotany was chosen as the method for selection of plants in order to 
increase the chances of finding a positive hit. The reasoning behind this 
was that if the plants were used medicinally then there was a high chance 
of the plants having antibacterial activity as well as low toxicity [49, 135]. 
Rongoa Māori can also provide other information such as which parts of 
the plant were likely to have activity and which season was best for 
collection. This can make the selection of plants easier to compile in order 
to increase the chance of attaining a positive hit, considering the 
thousands of species of NZ flora. Other plants with no traditional use were 
also selected, based on their physical properties (e.g. E. bidwilli is a 
parasitic plant) or their homology to other plants that were used 
medicinally (for example, M. umbellata compared to M. excelsa). Overall, 
this method of selection appeared to be advantageous as a 15% hit rate of 
active extracts was obtained from a small selection of extracts collected 
and tested.  
 
3.3.2 Method Validation 
Leaves were mainly chosen for sampling rather than bark, roots or flowers. 
This was because it was assumed that if secondary metabolites were the 
compounds present with antibacterial activity then they would logically be 
in the highest concentrations in the epidermal tissue in order to deter 
predators or pathogens [85].  Bark or flowers were generally only chosen if 
traditional medicine used those particular parts. However, the season at 
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time of collection could have affected the levels of compound present in 
the plant tissue. In order to conserve energy in the colder seasons the 
plant could have decreased the levels of metabolites present in the 
external tissue. An interesting result though was the leaf sample from M. 
laetum, which was taken in the winter and yet it was picked up in the 
screen as an active hit.  
  A desiccate was used as many plants were dried first when traditionally 
used [97]. It was also used to prevent water retention; otherwise the 
results would be affected by the presence of water remaining in the tissue.  
  Other non-polar solvents were also attempted for solvent extraction. 
Toluene, xylene and chloroform (CHCl3) were used for solvent extraction 
for some plant samples collected (results not shown). However, these 
solvents did not yield any positive results, including for those plants which 
had activity when extracted with polar solvents. Thus, only polar solvents 
were used for extraction as they were inexpensive and generated extracts 
with good antimycobacterial activity. EtOH and MeOH solvents were 
chosen as they have been considered effective solvents for liquid-
extraction of plant samples without degrading the tissue [136, 137]. SDW 
was also chosen as a solvent for extraction even though it does not extract 
compounds easily through the plants tough cellulose wall due to its high 
polarity [138]. Water was used for solvent extraction as many of the 
traditional preparations used in Rongoa Māori involved boiling the plant in 
water and then using the resulting liquid for treatment [97]. This was also 
the rationale for the incubation process, as it imitated the preparations 
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used in traditional Māori medicine with the intention of increasing the 
potency of the plants activity. 
The maceration procedure was performed in order to help increase 
solvent extraction by increasing surface area of the plant tissue. The heat 
was also thought to help increase the concentration of compounds 
extracted from the tissue. This was also facilitated by refrigeration after the 
incubation process. The extracts activity remained stable when stored at -
80°C, that is, they still retained antimycobacteria l activity when retested 
months later.  
  There were major differences noted in the activity of extracts between 
solvents used on the same sample. A possible explanation could be that 
one solvent was able to ‘extract more’ of the active component present in 
the sample, thus increasing the antimycobacterial activity. For example, if 
the active compound was an alkaloid there would be lower concentrations 
in an aqueous solution than in an alcohol solution. What was especially 
noted was that many of the aqueous extracts had better activity than the 
EtOH or MeOH extracts. This could be due to the possibility that the 
compounds were more stable in a ‘natural’ state than when in EtOH or 
MeOH, even though the aqueous solution is more polar and therefore 
unlikely to extract compounds through the plants cellulose membrane 
[138]. Overall, the variability between solvents justified the use of more 
than one solvent in order to maximise the hit rate of active extracts.  
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3.3.3 Initial screening of extracts against M. smegmatis 
Extracts from 7 plants species, Laurelia novae-zelandiae, Lophomyrtus 
bullata, Metrosideros excelsa, Myoporum laetum, Pittosporum tenuifolium, 
Pseudopanax crassifolius and Pseudowintera colorata showed inhibition 
towards M. smegmatis. In Rongoa Māori the flower of M. excelsa was 
used to treat sore throats [97, 121]. Lophomyrtus bullata, Myoporum 
laetum, Pittosporum tenuifolium and Pseudowintera colorata were either 
used for wounds, bruises or skin conditions [96, 121]. This lends to the 
idea that they potentially have antibacterial compounds. Pseudopanax 
crassifolius was the only extract with activity that was not traditionally used 
in Rongoa Māori medicine. The bark of Laurelia novae-zelandiae 
(Pukatea) was used by Māori in a number of medicinal remedies [121]. 
The bark had the best antimycobacterial activity against M. smegmatis 
with an MIC and IC50 of 0.04 mg/ml and 0.02 ± 0.004 mg/ml, respectively 
(Figure 3.2.7.1 A), indicating that the bark contained antibacterial 
compounds. It is possible that during development L. novae-zelandiae 
produced bioactive agents to act as protective measures against predators 
as well as for maintenance [85], thus signifying it as a good source for 
novel antitubercular compounds. This would need to be confirmed by 
validating the activity of the extract against M. tuberculosis, as well as 
establishing its type of activity. 
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4.1 Introduction 
In the previous chapter native plant samples were screened against M. 
smegmatis and seven plant species had extracts with antimycobacterial 
activity. The aim of this chapter was to then validate the bacteriostatic 
activity of these extracts against the slow-growing species M. bovis BCG 
and M. tuberculosis H37Ra. The extracts were then investigated for 
bactericidal activity against M. smegmatis. The extracts were also tested 
against E. coli and S. aureus for antibacterial activity. The active extracts 
potential cytotoxicity was also assessed. In addition, the potential 
compounds present in the active extracts are discussed. 
  M. tuberculosis H37Rv is a commonly used strain for the screening of 
antitubercular compounds in laboratories. However, it is restricted to 
physical containment level-3 facilities due to its virulent nature. Therefore 
other species of the mycobacterium genus have been utilized as a 
surrogate species for M. tuberculosis H37Rv. M. smegmatis and M. bovis 
BCG are therefore generally used for screening of compounds with 
potential antimycobacterial activity [139].  
  Mycobacterium bovis is an aerobic, slow-growing organism that is the 
causative agent of bovine TB in cattle. M. bovis is pathogenic and can 
cause TB in humans. M. bovis has a similar genome to M. tuberculosis 
with more than 99.9% homology in sequence [140] and so it is a suitable 
model when screening for antitubercular compounds. However, M. 
tuberculosis H37Ra was also used as it has the closest homology to the 
virulent strain M. tuberculosis H37Rv. By examining all three species it is 
possible to get an indication as to what type of inhibition is occurring, e.g. 
Chapter Four Validation of the Active Plant Extracts 
  55  
which of the three mycobacteria species are more susceptible to the active 
plant extracts. A blue dye, resazurin, that is oxidized to pink (resorufin) in 
the presence of live cells, was also used to test for the plant extracts 
bactericidal effect on cell viability [141, 142]. 
Escherichia coli and Staphylococcus aureus are part of our natural 
bacterial flora; however, these species are also the cause of many 
widespread diseases. E. coli is an opportunistic pathogen, usually the 
common source of food poisoning, but can also be the causal agent for 
neonatal meningitis [143]. S. aureus is one of the most widespread 
nosocomial infections and can cause the onset of serious diseases such 
as endocarditis, toxic shock syndrome (TSS) and even sepsis [144-146]. 
However, there is now the issue of drug-resistant strains of S. aureus, one 
of the major concerns in nosocomial infections [147]. In NZ it appears 
there is a progressive increase in the number of methicillin-resistant 
Staphylococcus aureus (MRSA) infections [148] and so there is also a 
need to search a variety of sources for novel antibacterial compounds.  
  Although plant extracts have been shown to be active against 
Mycobacteria they must also be non-toxic to humans. As M. tuberculosis 
infects macrophages in the lung, testing against a macrophage cell line 
presents a more comprehensible indication as to the extracts toxicity. In 
this research the murine macrophage cell-line J774 was used. A human 
cell-line HL-60 was also used for examination of the extracts cytotoxicity. 
HL-60 cells are also commonly used to study the cytotoxicity of anti-cancer 
drugs; however, they can also be applied for investigating the cytotoxicity 
of antimycobacterial extracts.   
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4.2 Results 
The seven species of active native plants were tested for 
antimycobacterial activity against M. bovis BCG, M. tuberculosis H37Ra 
and for their antibacterial activity against the clinically-important species E. 
coli and S. aureus.  
 
4.2.1 Summary of initial screening of active extracts against 
clinically-relevant species 
The extracts of L. novae-zelandiae, L. bullata, M. excelsa, M. laetum, P. 
tenuifolium, P. crassifolius and P. colorata were tested against M. bovis 
BCG and M. tuberculosis H37Ra. The use of GFP and OD were used to 
measure growth levels in M. smegmatis and M. bovis BCG whereas only 
OD was used for M. tuberculosis H37Ra, as it does not contain a plasmid 
with the GFP gene. However, GFP and OD are considered to have a 
correlation in measurement of growth levels. 
The leaf of P. tenuifolium was the most active extract with respect to M. 
tuberculosis with an IC50 of 0.51 mg/ml (Table 4.2.1). The bark extract of 
L. novae-zelandiae had an IC50 of 0.54 mg/ml against M. bovis and an IC50 
of 2.39 mg/ml against M. tuberculosis (Table 4.2.1, Figure 4.2.1). The 
cambium of L. novae-zelandiae was similarly active against both M. bovis 
and M. tuberculosis (Table 4.2.1, Figure 4.2.1) with an IC50 of 1.63 ± 0.21 
mg/ml and 1.86 ± 0.22 mg/ml, respectively. The leaf extract from M. 
laetum was not active against M. bovis or M. tuberculosis. To examine the 
specificity of the anti-bacterial activity of the plant extracts, the extracts 
were also tested against S. aureus and E. coli. The leaf of M. excelsa 
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which was active against M. smegmatis and to a lesser extent, M. 
tuberculosis, also displayed antibacterial activity towards S. aureus. The 
leaf of P. colorata was the most active of the extracts tested towards S. 
aureus with an IC50 of 0.43 mg/ml. None of the extracts tested exhibited 
anti-bacterial activity towards E. coli up to 10 mg/ml concentration.   
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Table 4.2.1. Comparison of MIC and IC50 values of active plant extracts with respect to M. smegmatis, M. bovis, M. tuberculosis, S. 
aureus and E. coli. M. smegmatis, M. bovis, S. aureus and E. coli values are based on GFP results and M. tuberculosis values are based on 
OD results. Extract and drug control values are in mg/ml. ‘±’ denotes standard error between triplicate results. MIC, Minimum Inhibitory 
Concentration. IC50, 50% inhibitory concentration. 
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Figure 4.2.1. Bacteriostatic inhibition curves for bark and cambium extracts 
of L. novae-zelandiae against M. bovis and M. tuberculosis. A) Inhibitory 
activity of AQ bark extract against M. bovis BCG and B) M. tuberculosis H37Ra. 
C) Inhibitory activity of MeOH cambium extract against M. bovis BCG and D) M. 
tuberculosis H37Ra. 100% represents complete growth of M. smegmatis cells 
compared to the untreated control. All values are in mg/ml. Error bars denote 
standard deviation between triplicate values. 
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4.2.2 Bactericidal screening of active extracts  
To elucidate the type of inhibitory activity, the active extracts were also 
tested for bactericidal activity. The results shown below in Figure 4.2.2 
show the bactericidal activity of each extract compared to its bacteriostatic 
activity. As bactericidal activity was measured using resazurin reduction 
the bacteriostatic results were also based on resazurin values. The leaf of 
M. laetum, P. tenuifolium and P. crassifolius appeared to have lost some 
bacteriostatic activity with the resazurin reduction, although this was likely 
due to auto-reduction by the extracts. The bark and cambium extracts of L. 
novae-zelandiae displayed considerable bactericidal activity at 
concentration of 2 mg/ml. The flower of M. excelsa and leaf of P. 
tenuifolium also had some bactericidal activity towards M. smegmatis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.2. Bactericidal activity of crude plant extracts with respect to M. 
smegmatis. All extracts had a starting concentration of 2 mg/ml. Values are 
based on Resazurin results. 100% represents no inhibition of M. smegmatis 
growth compared to the untreated control. Error bars denote standard deviation 
between triplicate values. 
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4.2.3 Cytotoxicity of active plant extracts 
Active extracts were tested against murine macrophage cell line J774 and 
human cell line HL-60 to give an indication of cytotoxicity. A cytotoxic 
compound, EpoA, was included as a positive control. As shown in Table 
4.2.3, EpoA had an IC50 of 5.32 x 10-6 ± 8.13 x 10-7 mg/ml and 2.91 x 10-6 
± 1.11 x 10-6 mg/ml against J774 and HL-60 cell lines, respectively. Using 
this value as the criteria for toxicity, all active extracts could be considered 
non-toxic. The flower extract of M. excelsa had the lowest IC50 value of 
2.34 ± ≤ 0.001 mg/ml towards the macrophages, whereas the bark of L. 
novae-zelandiae had the lowest value towards the HL-60 cells with an IC50 
of 13.64 ± 0.01 mg/ml. All of the extracts had lower IC50 values than the 
TB drug control RIF, which had an IC50 of 1.27 ± 2.25 mg/ml against J774 
cells and 0.12 ± 0.03 mg/ml against HL-60 cells. The results imply that the 
extracts were less toxic than the TB drug. 
Table 4.2.3. Cytotoxicity of active extracts against J774 and HL-60 cell-lines. 
The extracts were evaporated and resuspended in SDW to eliminate any bias 
 
Plant  
 
 
Part Used 
 
Cytotoxicity (IC50) 
   
J774 
 
HL-60 
 
 
L. novae-zelandiae 
 
Bark 
 
0.14 ± 0.02 
 
13.64 ± 0.01 
 Cambium 0.78 ± 0.05 0.63 ± 0.13 
L. bullata Leaf 0.24 ± 0.02 0.09 ± 0.01 
M. excelsa Leaf 0.03 ± 0.05 0.15 ± 0.001 
 Flower 2.34 ± ≤ 0.001 0.08 ± 0.005 
M. laetum Leaf 0.42 ± 0.07 0.94 ± 0.08 
P. tenuifolium Leaf 0.02 ± 0.003 0.04 ± 0.01 
P. crassifolius Leaf 0.17 ± 0.008 0.14 ± 0.007 
P. colorata Leaf 0.22 ± 0.02 0.15 ± 0.03 
RIF - 1.27 ± 2.25 0.12 ± 0.03 
EpoA 
 
- 5.32 x 10-6 ± 8.13 x 
10-7  
2.91 x 10-6 ± 1.11 x 
10-6  
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effect due to the EtOH or MeOH solvents. All values are in mg/ml. ‘±’ denotes 
standard error between triplicate results. 
4.3 Discussion 
4.3.1 Screening of active samples against clinically-relevant species 
Of the seven plant species found to be active against M. smegmatis, only 
six had antimycobacterial activity against the slow-growing species M. 
bovis and M. tuberculosis. The bark and cambium of L. novae-zelandiae 
were particularly active against the mycobacterium species and are 
discussed further in Sub-section 4.3.1.1. The flower of M. excelsa and leaf 
of P. tenuifolium had considerable activity against M. bovis and M. 
tuberculosis. In Rongoa Māori, M. excelsa was used for the treatment of 
sore throats and the leaf of P. tenuifolium was used to treat skin infections 
[97, 121]. Therefore, the antimycobacterial activities that were detected for 
M. excelsa and P. tenuifolium extracts of M. excelsa could relate to their 
traditional use. The flower of M. excelsa and leaf of P. tenuifolium also 
exhibited some substantial bactericidal activity and low cytotoxicity, 
lending further emphasis that these are extracts to focus on as sources of 
novel antitubercular compounds. The leaf of M. excelsa appeared to have 
lost activity when tested against M. bovis and M. tuberculosis, or in the 
case of the M. laetum extract had no activity at all. It could be that the 
extracts had activity specific to M. smegmatis. However, as the extracts 
did not have activity towards the slow-growing species they may not be 
considered worthy samples for further analysis for potential lead 
compounds.  
Only the leaf of P. colorata and M. excelsa displayed activity against S. 
aureus. Interestingly, none of the plant species tested exhibited 
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antibacterial activity towards E. coli. This suggested that the activity of the 
seven plant species might be specific to mycobacteria. Based on 
phylogeny with 16S ribosomal RNA, M. tuberculosis has similarities with 
gram-positive bacteria. This would correlate with the antibacterial activity 
against S. aureus that was observed with some of the extracts. However, 
Fu et al (2002) demonstrated that M. tuberculosis also has similarities with 
gram-negative bacteria like E. coli [149]. The extracts antimycobacterial 
activity could therefore be due to other features such as specific virulence 
factors or pathways. 
It should be mentioned that the MIC and IC50 values of the extracts against 
the different mycobacteria species (Table 4.2.1) were subject to variation 
due to differences in growth media used as well as assay incubation time. 
The activity of the extracts could also vary between mycobacterial species, 
with higher MIC and IC50 values towards M. bovis and M. tuberculosis due 
to slower metabolism. The compounds in the extract could have degraded 
over time before being able to fully act upon the mycobacterium’s growth. 
If this was the case then the extracts with higher MICs may not be suitable 
sources for new anti-TB compounds. 
It should also be noted that the MIC and IC50 of a crude extract is not a 
reliable indicator of activity. Aliquots of the same extract may have 
different concentrations of the antimycobacterial compound, or the extract 
may not have a highly active compound. For example, activity could be 
due to high concentrations of several moderately active antimycobacterial 
components rather than an individual component [150]. Further purification 
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techniques would have to be performed in order to clarify if the activity is 
due to a single agent or multiple compounds working in synergy. 
4.3.1.1 Antimycobacterial activity of Laurelia novae-zelandiae 
Bark and cambium extracts from Laurelia novae-zelandiae (Pukatea) 
(Figure 4.3.1.1) were the most active against M. smegmatis (Table 4.2.1). 
Furthermore, the bark and cambium extracts also displayed 
antimycobacterial activity against M. bovis and M. tuberculosis, exhibiting 
dose-response inhibition (Figure 4.2.1). The bark of L. novae-zelandiae 
was also the least toxic to HL-60 cells and non-toxic as well towards J774 
cells. The activity of Pukatea was of particular interest as the bark was 
medicinally used in Rongoa Māori to treat tubercular lesions [121]. The 
pulp of the cambium was boiled in water and the resulting liquid used for 
treating tubercular ulcers [97]. The antimycobacterial activity of the extract 
therefore correlated with the use of Pukatea to treat tubercular lesions in 
Rongoa Māori. The L. novae-zelandiae extract also displayed significant 
bactericidal activity against M. smegmatis, reinforcing the possibility that 
the bark of Pukatea contains previously unknown anti-tubercular 
compounds.      
Figure 4.3.1.1. Laurelia novae-zelandiae 
(Pukatea) from Otari-Wilton Bush 
Reserve. Pukatea is generally found in 
lowland forests areas [151]. It can grow up 
to 35 metres and possesses plank 
buttresses to support the tree’s growth in 
swamp areas [151]. A) Image of Pukatea 
with two main branches separating from 
the base of the tree. B) Plank buttress, a 
typical feature of Pukatea. 
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4.3.2 Potential bioactive compounds present 
Although the chemical basis for the anti-tubercular activity of the active 
extracts needs to be elucidated, earlier chemical studies have identified 
some compounds, as shown in Figure 4.3.2.  
 
 
Figure 4.3.2. Identified compounds in some native plants. Some compounds 
have already been identified in four of the plants that have exhibited 
antimycobacterial activity. 1. = Pukateine, 2. = Bullatenone, 3. = Ngaione, 4. = 
Polygodial. Pukateine reproduced from Dajas-Bailador F.A. et al (1999). 
Bullatenone, Ngaione and Polygodial adapted and reproduced from Woollard, 
J.M.R et al (2008), Sugimura T. et al (1993) and Taniguchi M et al (1988). 
Images created using SktechEl open source software downloable at 
[http://sourceforge.net/projects/sketchel].  
 
The compounds pukateine, bullatenone and ngaione have so far been 
isolated from NZ plants. Pukateine is a novel alkaloid isolated from the 
bark of Pukatea [152]. Pukateine is an analgesic similar to morphine, 
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which binds to the D2 dopamine receptor and acts as a dopaminergic 
agonist [153]. It also acts as an antagonist to the α1 adrenergic receptor 
[153, 154]. Bullatenone was isolated from L. bullata (Ramarama) [155] and 
is an antiseptic [98]. Chemical derivatives of bullatenone have been 
determined to have antibacterial properties against Bacillus subtilis [156]. 
The hepatotoxic sesquiterpene ngaione was found in the leaves of M. 
laetum (Ngaio) [157] and has been used in the treatment of athletes foot 
[98]. The leaves of P. colorata (Horopito) contain the compound polygodial 
[158], a drimane sesquiterpene that has been shown to be active against 
Candida albicans [103]. An interesting note is the fern B. fluviatile is also 
known to contain the compound polygodial [127] and yet it did not display 
any activity. The difference in activity between samples could be due to 
varying levels of polygodial present in each tissue. Finally, the flower of M. 
excelsa was determined to contain ellagic acid, which is a polyphenol 
antioxidant [98]. It is possible that compounds such as pukateine, 
bullatenone, ngaione, polygodial or ellagic acid may contribute to the anti-
bacterial activity of their plant extracts. These compounds offer a starting 
point for future studies to characterise the chemical basis of the 
antimycobacterial activity of L. novae-zelandiae, M. excelsa, L. bullata and 
P. colorata. 
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5.1 Introduction 
In the previous chapter, eight extracts were validated with 
antimycobacterial activity against M. tuberculosis. In this chapter the 
efficiency of extraction was investigated to determine if the activity of the 
extracts could be improved through various purification methods. Possible 
practical applications of some of the active extracts were also explored. 
  Size exclusion fractionation is the separation of compounds based on 
size. This is generally done by chromatography [159, 160] but the protocol 
has been modified for this research. The fractionation in this research 
involved centrifuging the extracts through filters of varying sizes. It was 
hypothesized that the activity of extracts could be improved by removing 
unwanted compounds. It could also provide information as to the general 
size of the compound(s) exhibiting antibacterial activity in the extracts. 
Solvent Phase Separation (SPS) is a form of liquid-liquid partitioning. This 
was a procedure used to separate two immiscible liquids in order to 
extract a substance or compound from one phase to another [161]. 
Therefore, SPS can be used to ‘purify’ a sample by removing unwanted 
compounds [161]. This type of extraction generally involved water and an 
organic solvent, in this case, Ethyl Acetate (EtOAc). EtOAc was chosen as 
a solvent for SPS as it is cheap, available and is commonly used in 
extractions [162]. Chloroform (CHCl3) was also used as a phase for SPS 
as it has also been previously used for liquid-liquid extraction with plant 
samples [163]. Combinations of different fractionation techniques were 
also applied. 
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This chapter also involved an initial study involving the utilization of the 
active extracts in a practical application. The active extracts from L. novae-
zelandiae, M. excelsa and P. colorata were added to an aqueous cream 
and tested against M. smegmatis and S. aureus. Based on these initial 
results the active extracts could potentially be used, for example, for the 
treatment of skin infections in the form of a cream-based solution. 
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5.2 Results 
The nine active extracts were subjected to numerous purification 
techniques. This included techniques such as size exclusion fractionation 
and solvent phase separation. The leaf of L. bullata, M. laetum, P. 
tenuifolium and P. crassifolius lost antimycobacterial activity upon 
application of these purification techniques and so were not included in the 
results. Thus, the following section will focus on the bark and cambium 
extracts of L. novae-zelandiae, the leaf and flower of M. excelsa and the 
leaf of P. colorata. 
 
5.2.1 Activity of aqueous extracts tested against M. smegmatis 
Due to the slight toxicity of some solvents used for extraction, it was 
investigated if the crude extracts could retain activity when the solvent was 
evaporated and the sample resuspended in SDW. The rationale was that 
water extracts were easier to purify, as the filters used would be destroyed 
by the EtOH or MeOH. Table 5.2.1 gives the activity of the extracts when 
resuspended in SDW. The bark of L. novae-zelandiae was already an AQ 
extract and so retained antimycobacterial activity. The remaining extracts 
appeared to have lost activity, with a high MIC and IC50 when tested 
against M. smegmatis. However, it must be taken into consideration that 
these values are a measure of potency rather than actual concentration of 
an active compound, which most likely varies between extracts. 
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Table 5.2.1. Comparison of MIC and IC50 values of crude and aqueous plant 
extracts with respect to M. smegmatis. Extracts were evaporated and 
resuspended in SDW and examined to determine if activity was retained in an 
aqueous solution. All values are in mg/ml and based on GFP results. ‘±’ denotes 
standard error between triplicate results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plant 
 
Part 
  
Crude 
 
  
In AQ 
 
 
   
MIC 
 
IC50 
  
MIC 
 
IC50 
 
L. novae-
zelandiae 
 
Bark 
  
 0.04 
 
0.02 ± 0.004 
  
0.04 
 
0.0006 ± 
0.004 
  
Cambium 
  
0.50 
 
0.25 ± 0.01 
  
2.5 
 
1.52 ± 0.18 
 
M. excelsa 
 
Leaf 
  
0.63 
 
0.11 ± 0.06 
  
10 
 
0.33 ± 0.07 
  
Flower 
  
0.63 
 
0.41 ± 0.06 
  
5 
 
0.06 ± 0.02 
 
P. colorata 
 
 
Leaf 
  
1.25 
 
0.74 ± 0.40 
  
10 
 
2.14 ± 1.49 
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5.2.2 Size exclusion fractionation of active extracts 
Fractionation of active samples was performed via size exclusion. The 
extracts were evaporated and resuspended in SDW before passed 
through a 30 kDa filter followed by a 3 kDa filter. The filtrate and retentate 
for each size were retained. The resulting samples were then evaporated 
and resuspended in SDW before analysis of antimycobacterial activity 
against M. smegmatis in a bacteriostatic assay. The levels of 
antimycobacterial activity shown in Figure 5.2.2 indicates that the bark 
from L. novae-zelandiae, flower from M. excelsa and leaf from P. colorata 
most likely have bioactive components that are smaller than 3 kDa. The 
cambium of L. novae-zelandiae and leaf of M. excelsa appear to have 
compounds exhibiting antimycobacterial activity that is smaller than 30 
kDa but larger than 3 kDa. An interesting note is that the bark of L. novae-
zelandiae had constant antimycobacterial activity across all fraction sizes. 
However, size exclusion work is subject to significant variation, especially 
when working with crude samples where the concentration of the active 
component(s) is unknown. 
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Figure 5.2.2. Comparison of different size fractions of active plant extracts. 
Extracts were resuspended in SDW before fractionation by size exclusion and 
tested against M. smegmatis in a bacteriostatic assay. All extracts were tested at 
a concentration of 1 mg/ml. These values are based on the GFP results. 100% 
represents no inhibition of M. smegmatis growth compared to the untreated 
control. Error bars denote standard deviation between triplicate values. 
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5.2.3 Solvent Phase Separation of active extracts 
Two different liquids, EtOAc and CHCl3, were used for SPS for the active 
extracts in order to purify the samples by liquid extraction of unwanted 
compounds. 
 
5.2.3.1 SPS of active extracts with Ethyl Acetate 
Liquid-liquid partitioning with the active samples was performed via SPS with 
EtOAc. The extracts were evaporated and resuspended in SDW before being 
purified via liquid partitioning with EtOAc. After solvent phase separation 
(SPS) the AQ (extract) layer was removed, evaporated and resuspended in 
SDW again before examination against M. smegmatis in a bacteriostatic 
assay. The crude extracts were also subjected to SPS with EtOAc (i.e. no 
resuspension in SDW) as a comparison to the original activity of the extracts 
in its crude form. There was significant bacteriostatic inhibition of 
mycobacteria growth for the L. novae-zelandiae extracts; however, the bark 
of L. novae-zelandiae had better antimycobacterial activity as a crude 
sample. It should be noted that the EtOAc layer was also tested when solvent 
phase separated with the AQ and crude layer and was found to have no 
antimycobacterial activity for either condition (results not shown). 
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Figure 5.2.3.1. Comparison of crude and AQ extracts activity when purified 
with EtOAc through SPS. Extracts were solvent phase separated from EtOAc and 
then tested against M. smegmatis. All extracts were tested at a concentration of 1 
mg/ml. These values are based on the GFP results. 100% represents no inhibition 
of M. smegmatis growth compared to the untreated control. Error bars denote 
standard deviation between triplicate values. 
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5.2.3.2 SPS of active extracts with Chloroform 
The crude extracts were purified via SPS with CHCl3 to determine if activity 
of the extracts could be improved. After SPS, the extract layer was removed 
and evaporated before resuspension in SDW. The CHCl3 layer was also 
removed and evaporated before resuspension in DMSO, so as to dissolve 
any residual plant tissue in the CHCl3 layer. The results as displayed in 
Figure 5.2.3.2 indicate that the extracts from L. novae-zelandiae, M. excelsa 
and P. colorata had significant inhibitory activity. The CHCl3 layer also 
appeared to have antimycobacterial activity exhibited from some of the 
extracts. In fact, for the cambium extract from L. novae-zelandiae and leaf 
extract from P. colorata, the CHCl3 layer exhibited similar or better inhibition 
levels against M. smegmatis than the extract layer.  
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Figure 5.2.3.2. Comparison of SPS with Chloroform (CHCl3) purified plant 
extracts. The extract layer and Chloroform layer were examined against M. 
smegmatis in a bacteriostatic assay. All extracts were tested at a concentration of 1 
mg/ml. These values are based on the GFP results. 100% represents no inhibition 
of M. smegmatis growth compared to the untreated control. Error bars denote 
standard deviation between triplicate values. 
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5.2.3.3 Combination of Purification techniques 
A combination of previous techniques was applied in order to observe an 
improvement in activity. The extracts were evaporated and resuspended in 
SDW before purification via size exclusion with a 30 kDa filter. The filtrate 
was then solvent phase separated with EtOAc. The aqueous layer was 
removed, evaporated and resuspended again in SDW before being screened 
against M. smegmatis in a bacteriostatic assay. In Figure 5.2.3.3 it can be 
observed that there was still significant activity exhibited in the bark extract 
from L. novae-zelandiae and the M. excelsa extracts. In comparison to the 
SPS with EtOAc, only the bark extract of L. novae-zelandiae and M. excelsa 
extracts had improved activity with the addition of 30 kDa fractionation. It is 
important to note that this is only an indication of improved efficiency of 
extraction as there is bound to be variability among results with crude 
extracts. 
 
Chapter Five                       Efficiency and delivery of Plant Extract activity 
  79  
 
Figure 5.2.3.3. Bacteriostatic activity of purified plant extracts with respect to 
M. smegmatis. Extracts were subjected to 30 kDa size exclusion fractionation and 
SPS with EtOAc. All extracts were tested at a concentration of 1 mg/ml. Values are 
based on GFP results. 100% represents no inhibition of M. smegmatis growth 
compared to the untreated control. Error bars denote standard deviation between 
triplicate values. 
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5.2.4 Practical application of L. novae-zelandiae and other extracts 
Seven plants have been identified with antimycobacterial activity and part of 
this research has involved improving the efficiency of extraction in order to 
improve activity. Another aspect to consider is the use of this research. One 
notion was whether the active hits could be used in a practical application. 
For example, a moisturizing cream containing natural extracts that could 
have potential inhibitory effects against skin infections. In this study four of 
the active extracts were tested in an aqueous cream form against M. 
smegmatis and S. aureus. S. aureus is known to cause skin infections [144], 
which is why it was also included in the practical application. The bark and 
cambium of L. novae-zelandiae were tested as they were traditionally used 
for the treatment of tubercular ulcers on the skin. The leaf of M. excelsa and 
P. colorata were also tested as they were the only extracts tested to have 
activity against S. aureus. As shown below in Figure 5.2.4 and Table 5.2.4 it 
appears that the extracts (with the exception of the leaf extract of M. excelsa) 
lose activity in the aqeous cream form.  
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Figure 5.2.4. Disc Diffusion of active extracts in an aqueous cream against M. 
smegmatis and S. aureus. Extracts from L. novae-zelandiae, M. excelsa and P. 
colorata were tested in an aqueous cream form against M. smegmatis (Left column) 
and S. aureus (Right column). Layout is as follows; 1. = Negative control aqueous 
cream with no extract added, 2. = Positive control Rifampin (1 mg/ml), 3. = Extract 
added to an aqueous cream (0.5 % w/v), 4. = Extract alone (1 mg/ml). 
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Table 5.2.4 gives the zones of inhibition that were measured around the 
discs. The leaf of M. excelsa was the only extract to have activity against M. 
smegmatis in the aqueous cream form. None of the extracts had activity 
against S. aureus when added to the aqueous cream solution. All extracts 
displayed activity against M. smegmatis when the extract alone was tested, 
confirming their activity in liquid and solid conditions. However, all extracts 
also displayed activity against S. aureus, when only the M. excelsa and P. 
colorata extracts displayed antibacterial activity against S. aureus in the liquid 
assay. 
 
 
Plant Extract 
 
Condition 
 
Zone of inhibition (mm) 
 
 M. smegmatis S. aureus 
 
L. novae-zelandiae 
 
Bark + Cream 
 
0 
 
0 
 Bark 1 2 
 Cambium + Cream 0 0 
 Cambium 1 4 
M. excelsa  Leaf + Cream 2 0 
 Leaf 5 4 
P. colorata  Leaf + Cream 0 0 
 Leaf 0 10 
Aqueous Cream  - 0 0 
Rifampin - 10 18 
 
Table 5.2.4. Inhibitory activity of extracts in a cream-based solution. Active 
extracts from the plants L. novae-zelandiae, M. excelsa and P. colorata were 
applied to an aqueous cream and tested against M. smegmatis and S. aureus for 
any inhibitory activity in a cream-based solution. Listed are the zones of inhibition 
(mm) surrounding the discs. 
 
Chapter Five                       Efficiency and delivery of Plant Extract activity 
  83  
5.3 Discussion 
5.3.1 Purification techniques 
  The proposition was that the purification techniques used would improve the 
activity of the bioactive extracts. Due to the harsh properties of the polar 
solvents used for extraction, the crude extracts had to be resuspended in 
SDW before the purification techniques were performed. Size exclusion 
fractionation was employed so that the large compounds with no activity in an 
extract were removed, thus purifying and increasing the potency of the active 
compounds. This could be due to an increase in relative concentration of the 
active compound, or perhaps the reduction of unwanted molecules, allowing 
‘easier’ access to the active compounds target. However, the L. novae-
zelandiae bark extract displayed similar activity across all fractions. A 
possible explanation was that the active constituent in the sample was a 
small compound (less than 3 kDa) that got ‘trapped’ with the larger, bulkier 
compounds in the filters. There was also the possibility of synergistic activity 
occurring, when more than one compound was working concurrently in the 
extract. If said compounds were of different size range then levels of activity 
would decrease. Overall, the use of size exclusion fractionation did not show 
a marked increase in antimycobacterial activity, but it did give an indication 
as to the general size of the bioactive compounds. 
 The purification techniques did improve the activity of the crude extracts 
when they were resuspended in SDW. The bark of L. novae-zelandiae was 
the only extract to display bactericidal activity with any of the purification 
techniques, notably size exclusion filtration combined with SPS of EtOAc. 
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However, there was no significant improvement in activity compared to the 
crude extract (See Table 4.2.1).  
Speculation suggests that the loss in antimycobacterial activity was due to 
the resuspension in SDW. Thus, the chemical environment was changed and 
therefore disrupted the nature of the bioactive components present in the 
extract, similar to that of Le Chatelier’s Principle [164]. It proposes that if 
something is altered in the environment, there will be a reaction to make up 
for that change. P. colorata (Horopito) is already marketed for antibacterial 
purposes as a crude extract, demonstrating that perhaps in order to retain 
activity the plant extracts are best kept as close to the original state as 
possible. 
The CHCl3 layer displayed antimycobacterial activity for seven of the active 
extracts. The CHCl3 layer could consequently provide some novel 
compounds that could be isolated for further chemical analysis, provided the 
compounds remain stable in a purified state.  
Overall, it appears the purification techniques did not improve the extracts 
activity in its original solvent. The bark of L. novae-zelandiae and leaf of M. 
laetum were AQ extracts that did not have improved activity, instead they had 
decreased activity upon purification. This suggests that the purification 
techniques were not suitable for AQ extracts, possibly due to their inorganic 
nature. Future purification work would involve chemical analysis with more 
organic solvents.  
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5.3.2 Practical Application 
It was investigated as to whether the extracts from L. novae-zelandiae, M. 
excelsa, and P. colorata could be delivered in a feasible way. The advantage 
of this application was that the extracts could be used in a crude state, rather 
than having to work with an individual compound, as many skin cream 
products use natural extracts. It appeared that when the extracts were added 
to the aqueous cream, the extracts lost activity against both species tested, 
with the exception of the leaf of M. excelsa. This could possibly be due to the 
cream interfering with the plant extracts activity. However, it could also have 
been due to the low concentrations of extract in the aqueous cream, due to 
limitation of sample quantity available. What was interesting, however, was 
the inhibition exhibited by both L. novae-zelandiae against S. aureus, when 
none was previously exhibited in the liquid bacteriostatic assay. It could be 
speculated that the L. novae-zelandiae extracts had activity against S. 
aureus when the bacteria were grown on solid media than when in culture, 
suggesting a possible different mode of inhibition occurring of the extracts 
activity against S. aureus. 
M. excelsa leaf extract displayed activity against M. smegmatis in an 
aqueous cream based solution as well as when tested with extract alone. 
This was interesting as the extract was resuspended in SDW and has been 
previously shown to have a drastic reduction in activity when in the extract is 
in an AQ solution. It could be speculated that the activity of the M. excelsa 
leaf was better in a more solid-based condition. In addition, the bark of L. 
novae-zelandiae was considered a more likely candidate for activity against 
M. smegmatis in the cream form, yet it did not display antimycobacterial 
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activity when added to the aqueous cream. However, its activity may be 
dependent on a liquid-based solution. Overall, other factors have to be 
included in order to create a cream-based product with marketable activity. 
There is the possibility of combinating the active extracts, (L. novae-
zelandiae, M. excelsa and P. colorata) together in an aqueous cream. It 
could be feasible to apply these active extracts in a practical delivery system 
for antibacterial treatment. 
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6.1 Summary of Research 
  There is now more emphasis on analysing natural products as sources of 
novel drugs. The objective of this research was to test native NZ plants for 
antimycobacterial activity. This involved building a library of native NZ 
plants, developing a protocol for extracting the potential antitubercular 
compounds and then testing them against mycobacterial species. A library 
of 58 native NZ samples from 46 plant species was compiled from various 
locations and solvent extraction performed to give a total of 174 extracts. 
Drawing on knowledge from Rongoa Māori, nine extracts from seven 
native plant species demonstrated activity against M. smegmatis in the 
initial screen. Further validation led to the identification of eight extracts 
from L. novae-zelandiae, L. bullata, M. excelsa, P. tenuifolium, P. 
crassifolius and P. colorata that had activity against the clinically relevant 
slow-growing species M. bovis and M. tuberculosis H37Ra, suggesting the 
presence of potential antitubercular compounds. Extracts were also tested 
against S. aureus and E. coli for potential antibacterial activity and it was 
found that the activity suggested specificity to the mycobacteria. In 
addition, the extracts were non-toxic to murine macrophages and human 
cell-lines compared to the current TB drug RIF, thus indicating these 
extracts are worthy candidates for further research. 
  This study also involved improving the efficiency of extraction as well as 
investigating a potential delivery system of the active extracts. The 
efficiency of compound extraction from the plant’s tissue was somewhat 
improved with the various purification techniques used. It was intended 
that the bioactive compounds have improved antimycobacterial activity 
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upon purification, but it was found that this was generally not the case. In 
terms of a practical application such as a skin cream, this was a feasible 
proposal, as many natural remedies include natural products that are 
effective in their delivery and efficacy. The results showed that the extract 
lost activity instead when applied in an aqueous cream; however, other 
delivery systems of the bioactive extracts could still be explored. For 
example, the extracts could be taken as an herbal supplement in pill form. 
  There is an increased interest in identifying the compounds responsible 
for the anti-mycobacterial activity of plants and developing them as 
potential new TB drugs. With a high endemic rate of diverse NZ flora this 
research provides a starting point for discovering unique bioactive extracts 
that could lead to novel antitubercular drugs, using traditional Māori 
medicine as a basis for selection.  
  The flower of M. excelsa and leaf of P. tenuifolium exhibited substantial 
bacteriostatic and bactericidal activity against mycobacteria, which could 
relate to their traditional use in Rongoa Māori. The bark of L. novae-
zelandiae (Pukatea) was used in traditional medicine for the treatment of 
TB, correlating with the extracts antimycobacterial activity. For that reason 
the use of ethnomedicine (Rongoa Māori) was an effective method of 
sample selection. Furthermore, both the bark and cambium extracts of 
Pukatea had significant bactericidal activity against mycobacteria, 
signifying that Pukatea contains potential novel antitubercular compounds. 
Compounds such as pukateine from L. novae-zelandiae, ellagic acid from 
M. excelsa and bullatenone from L. bullata could provide insight into the 
type of activity in their plant extracts. Therefore, the bark of L. novae-
Chapter Six                                                 Summary and Future Directions 
 
  90  
zelandiae, leaf and flower of M. excelsa and leaf of L. bullata are excellent 
candidates for future chemical analysis for the development of novel drugs 
to help combat TB. 
 
6.2 Critique of the Research 
Although many drugs today are derived from plants there are limitations to 
researching natural extracts as a source of lead compounds. It is 
expensive in time and funding to extract, screen and separate compounds 
with potent antimycobacterial activity that merit further analysis. Often 
there is low yield of the desired compound from the extract, or it is not 
stable in a purified state. The fractionation process was based on the 
notion that the active compound in the purified extract was simple and 
stable, retained activity and did not have synergistic activity with other 
compounds in the extract [49, 150]. There was also the possibility that the 
compound was not as active in vivo compared to activity in vitro. With 
these potential setbacks the potential lead compounds are then less likely 
to make it to clinical drug trials. For this reason there are still many plants 
with potential activity that have yet to be properly assessed as sources of 
lead compounds.  
However, it can be speculated that plants that have been used in 
traditional medicine are more likely to contain potential lead compounds as 
they have medicinal properties and are likely to be non-toxic to the patient. 
Furthermore, in traditional medicine crude extracts are used and therefore 
the bioactive compound must be reasonably effective if the patient 
receives a low dosage. 
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Another issue is that even if the bioactive compound is simple and retains 
activity in an isolated form, it may not be novel and could already have 
been marketed [49]. Although some compounds have already been 
identified to be present in other plants (e.g. polygodial in Horopito), it is 
thought that NZ plants are still likely to contain novel compounds due to 
the diverse flora and its isolation from other countries. Some compounds 
already identified have been found to be unique to NZ plants, e.g. 
Pukateine in Pukatea, Bullatenone in Ramarama and Ngaione in Ngaio. 
So there is a significant possibility that compounds pertaining to the NZ 
bioactive extracts activity are not novel.  
  
6.3 Future Directions 
  There is a growing interest in identifying the compounds responsible for 
the antimycobacterial activity of extracts used in traditional medicines and 
developing them as potential new TB drugs. Future studies should 
therefore focus on isolating the bioactive compounds in extracts with 
validated antimycobacterial activity, such as Pukatea. This can be done by 
means of Mass Spectrometry (MS), High-Pressure-Liquid-
Chromatography (HPLC) and Nuclear Magnetic Resonance (NMR). HPLC 
is a rapid and concise technique, providing accurate results with high 
specificity and good resolution [165, 166]. Bioassay-guided fractionation 
could be applied in order to ascertain the active constituents in a crude 
extract [150]. Mass spectrometry would be applied for broad identification 
of chemical composition of compounds present, whereas NMR would be 
employed in order to elucidate the structure of novel compounds with 
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activity. NMR is an effective method as it can quickly identify unique 
structures with few resources needed for analysis [49]. These active 
compounds would then be tested against M. tuberculosis H37Ra in vitro to 
ensure bacteriostatic and bactericidal activity is retained. The compounds 
would also be analysed in vivo against the virulent strain such as M. 
tuberculosis H37Rv to confirm antimycobacterial activity in an infected 
host.  
  Once the compounds of interest have been determined future studies 
would involve synthesizing derivatives of the compound with the purpose 
of improving efficacy or decreasing cytotoxicity. It would be desirable to 
isolate an active compound that has a simple structure, thus allowing 
basic derivatives to be manufactured. It would also be beneficial to have a 
novel mechanism of action (MOA) so as to decrease the possibility of 
cross-resistance with current TB drugs [167].  
  As the activity of the extracts in the application of a skin cream was 
ineffective, other delivery systems could still be investigated. The bioactive 
extracts could be applied in the form of an aerosol spray, or the extracts 
could be ingested as an herbal supplement. This is a successful 
application for Kolorex® (New Zealand), which markets kolorXtract™, 
herbal capsules and teas containing extracts of P. colorata which are used 
to help maintain intestinal microflora [168]. Nutraceuticals are becoming a 
promising area of research, introducing herbal supplements to the drug 
market rather than individual compounds [169]. Therefore, NZ plant 
extracts could be investigated as a source of adjuvants for TB drugs. A 
medical dictionary describes an adjuvant as an agent that increases the 
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efficacy of an already existing drug without increasing its cytotoxicity. The 
drug Dzherelo™ (Immunoxel) is an herbal adjuvant for TB and is derived 
from a combination of aqueous-alcohol plant extracts including Aloe, 
Yarrow, Nettle, Dandelion, Marigold, Wormwood, and Juniper fruit [170, 
171]. Dzherelo™ is a phytoconcentrate of plant extracts and has shown to 
increase the efficacy of TB drugs in recent clinical trials [170]. The trials 
also indicated that the herbal adjuvant decreased cytotoxic damage 
caused by current TB drugs as well as decreased treatment time. This 
clinical drug trial also included individuals infected with MDR-TB as well as 
individuals co-infected with HIV [170-173]. Thus, the addition of 
Dzherelo™ produced an overall enhanced TB therapy by reducing 
treatment time and treating drug-resistant cases. Therefore, the bioactive 
extracts could be tested in combination with current TB drugs and 
establish if there is improved efficacy and/or decreased toxicity.  
Future experiments could also involve bacteriostatic assays against other 
clinically important organisms such as Streptococcus pneummoniae and 
Pseudomonas aeruginosa. As Rongoa Māori was an effective form of 
plant selection it could be used as a starting point for studying the 
bioactivity of native plants against other bacteria. With many unique plants 
that were used in Rongoa Māori the potential medicinal value of NZ flora 
warrants further investigation. 
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In conclusion, with the use of Rongoa Māori this study identified seven 
native plant species with antimycobacterial activity, two of which contained 
antibacterial properties. In particular, the antimycobacterial activity of the 
bark extract of Pukatea justified its traditional use in Māori medicine. 
Overall, the native bioactive extracts in this research could be of an 
interest in drug discovery and offer an excellent source of potential novel 
anti-tubercular compounds.  
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APPENDICES 
 
 
Appendix 1: Research article in BMC Complementary and Alternative 
Medicine 
Results from the initial screen of the plant extracts against M. smegmatis 
(Section 3.2.6) and the screening against clinically-relevant species 
(Section 4.2.1) were peer-reviewed and published in the journal BMC 
Complementary and Alternative Medicine (2010), 10(1):25. Below is the 
research article from the journal. 
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Appendix 2: Bacteriostatic inhibition curves of extracts with activity 
against M. smegmatis 
 
Dose-response experiments were performed on the active extracts that 
were found to have ≥ 90% inhibition in the initial screen against M. 
smegmatis. Figure A.2 depicts the bacteriostatic curves for the active 
extracts from L. bullata, M. excelsa, M. laetum, P. tenuifolium, P. 
crassifolius and P. colorata species. 
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Figure A.2. Bacteriostatic inhibition curves of active extracts against M. 
smegmatis. A) MeOH leaf extract L. bullata, B) MeOH leaf extract of M. excelsa, 
C) EtOH flower extract of M. excelsa, D) AQ leaf extract of M. laetum, E) EtOH 
leaf extract of P. tenuifolium, F) EtOH leaf extract of P. crassifolius, G) MeOH leaf 
extract of P. colorata. Values are based on GFP results. 100% represents 
complete growth of M. smegmatis cells compared to the untreated control. Error 
bars denote standard deviation between triplicate values. 
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